0001628280-18-014380.txt : 20181114 0001628280-18-014380.hdr.sgml : 20181114 20181114171625 ACCESSION NUMBER: 0001628280-18-014380 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 181185100 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 10-Q 1 cpix-20180930.htm 10-Q Document
Non-accelerated Filer9/30/20182018Q3FALSEFALSEFALSE--12-310001087294——100,000,000100,000,00015,555,86515,723,07515,555,86515,723,075P1YP3Y00010872942018-01-012018-09-30xbrli:shares00010872942018-11-09iso4217:USD00010872942018-09-3000010872942017-12-31iso4217:USDxbrli:shares00010872942018-07-012018-09-3000010872942017-07-012017-09-3000010872942017-01-012017-09-3000010872942016-12-3100010872942017-09-300001087294us-gaap:CommonStockMember2017-12-310001087294us-gaap:RetainedEarningsMember2017-12-310001087294us-gaap:NoncontrollingInterestMember2017-12-310001087294us-gaap:CommonStockMember2018-01-012018-09-300001087294us-gaap:RetainedEarningsMember2018-01-012018-09-300001087294us-gaap:NoncontrollingInterestMember2018-01-012018-09-300001087294us-gaap:CommonStockMember2018-09-300001087294us-gaap:NoncontrollingInterestMember2018-09-30cpix:Segment0001087294cpix:UsTreasuryNotesAndBondsSecuritiesMemberMemberus-gaap:FairValueInputsLevel1Member2018-09-300001087294cpix:UsTreasuryNotesAndBondsSecuritiesMemberMemberus-gaap:FairValueInputsLevel2Member2018-09-300001087294cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember2018-09-300001087294cpix:UsTreasuryNotesAndBondsSecuritiesMemberMemberus-gaap:FairValueInputsLevel1Member2017-12-310001087294cpix:UsTreasuryNotesAndBondsSecuritiesMemberMemberus-gaap:FairValueInputsLevel2Member2017-12-310001087294cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember2017-12-310001087294us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel1Member2018-09-300001087294us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel2Member2018-09-300001087294us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2018-09-300001087294us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel1Member2017-12-310001087294us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel2Member2017-12-310001087294us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2017-12-310001087294us-gaap:FairValueInputsLevel1Memberus-gaap:AgencySecuritiesMember2018-09-300001087294us-gaap:FairValueInputsLevel2Memberus-gaap:AgencySecuritiesMember2018-09-300001087294us-gaap:AgencySecuritiesMember2018-09-300001087294us-gaap:FairValueInputsLevel1Memberus-gaap:AgencySecuritiesMember2017-12-310001087294us-gaap:FairValueInputsLevel2Memberus-gaap:AgencySecuritiesMember2017-12-310001087294us-gaap:AgencySecuritiesMember2017-12-310001087294us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Member2018-09-300001087294us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2018-09-300001087294us-gaap:CorporateBondSecuritiesMember2018-09-300001087294us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Member2017-12-310001087294us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2017-12-310001087294us-gaap:CorporateBondSecuritiesMember2017-12-310001087294cpix:LoanPoolsMemberus-gaap:FairValueInputsLevel1Member2018-09-300001087294cpix:LoanPoolsMemberus-gaap:FairValueInputsLevel2Member2018-09-300001087294cpix:LoanPoolsMember2018-09-300001087294cpix:LoanPoolsMemberus-gaap:FairValueInputsLevel1Member2017-12-310001087294cpix:LoanPoolsMemberus-gaap:FairValueInputsLevel2Member2017-12-310001087294cpix:LoanPoolsMember2017-12-310001087294us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel1Member2018-09-300001087294us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2018-09-300001087294us-gaap:MunicipalBondsMember2018-09-300001087294us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel1Member2017-12-310001087294us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2017-12-310001087294us-gaap:MunicipalBondsMember2017-12-310001087294us-gaap:FairValueInputsLevel1Member2018-09-300001087294us-gaap:FairValueInputsLevel2Member2018-09-300001087294us-gaap:FairValueInputsLevel1Member2017-12-310001087294us-gaap:FairValueInputsLevel2Member2017-12-310001087294cpix:AcetadoteMember2018-07-012018-09-300001087294cpix:AcetadoteMember2017-07-012017-09-300001087294cpix:AcetadoteMember2018-01-012018-09-300001087294cpix:AcetadoteMember2017-01-012017-09-300001087294cpix:OmeclamoxPakMember2018-07-012018-09-300001087294cpix:OmeclamoxPakMember2017-07-012017-09-300001087294cpix:OmeclamoxPakMember2018-01-012018-09-300001087294cpix:OmeclamoxPakMember2017-01-012017-09-300001087294cpix:KristaloseMember2018-07-012018-09-300001087294cpix:KristaloseMember2017-07-012017-09-300001087294cpix:KristaloseMember2018-01-012018-09-300001087294cpix:KristaloseMember2017-01-012017-09-300001087294cpix:VaprisolMember2018-07-012018-09-300001087294cpix:VaprisolMember2017-07-012017-09-300001087294cpix:VaprisolMember2018-01-012018-09-300001087294cpix:VaprisolMember2017-01-012017-09-300001087294cpix:CaldolorMember2018-07-012018-09-300001087294cpix:CaldolorMember2017-07-012017-09-300001087294cpix:CaldolorMember2018-01-012018-09-300001087294cpix:CaldolorMember2017-01-012017-09-300001087294cpix:EthyolMember2018-07-012018-09-300001087294cpix:EthyolMember2017-07-012017-09-300001087294cpix:EthyolMember2018-01-012018-09-300001087294cpix:EthyolMember2017-01-012017-09-300001087294cpix:TotectMember2018-07-012018-09-300001087294cpix:TotectMember2017-07-012017-09-300001087294cpix:TotectMember2018-01-012018-09-300001087294cpix:TotectMember2017-01-012017-09-300001087294cpix:OtherProductsMember2018-07-012018-09-300001087294cpix:OtherProductsMember2017-07-012017-09-300001087294cpix:OtherProductsMember2018-01-012018-09-300001087294cpix:OtherProductsMember2017-01-012017-09-3000010872942010-05-1300010872942016-01-310001087294us-gaap:CommonStockMember2017-01-012017-09-3000010872942017-11-012017-11-300001087294us-gaap:RestrictedStockMember2018-01-012018-09-300001087294us-gaap:RestrictedStockMember2017-01-012017-09-300001087294us-gaap:SubsequentEventMemberus-gaap:RevolvingCreditFacilityMembercpix:SecondAmendmentMembercpix:PinnacleBankMember2018-10-170001087294us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembercpix:PinnacleBankMember2017-07-31xbrli:pure0001087294srt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembercpix:PinnacleBankMember2017-07-310001087294us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMembercpix:PinnacleBankMember2017-07-310001087294us-gaap:LineOfCreditMembercpix:SunTrustBankMemberus-gaap:RevolvingCreditFacilityMember2018-09-300001087294us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembercpix:PinnacleBankMember2017-07-312017-07-310001087294us-gaap:DirectorMemberus-gaap:RestrictedStockMember2018-01-012018-09-300001087294us-gaap:SubsequentEventMembercpix:VIBATIVMember2018-11-062018-11-060001087294us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembercpix:PinnacleBankMember2018-09-300001087294us-gaap:SubsequentEventMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembercpix:PinnacleBankMember2018-10-012018-10-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549 
FORM 10-Q 
(Mark One)
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2018 
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to             .
Commission file number: 001-33637 
Cumberland Pharmaceuticals Inc. 
(Exact Name of Registrant as Specified In Its Charter)
Tennessee
62-1765329
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer
Identification No.)
2525 West End Avenue, Suite 950,
Nashville, Tennessee
37203 
(Address of Principal Executive Offices)
(Zip Code)
(615) 255-0068
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
¨
Accelerated filer
¨
Non-accelerated filer
ý
Smaller reporting company
¨
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ¨    No  ý
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Class
  Outstanding at November 9, 2018 
Common stock, no par value
15,527,623 



CUMBERLAND PHARMACEUTICALS INC.
INDEX



PART I – FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)
September 30, 2018December 31, 2017 
ASSETS 
Current assets: 
Cash and cash equivalents $38,259,233 $45,412,868 
Marketable securities 9,533,703 4,672,476 
Accounts receivable, net 7,055,138 8,395,112 
Inventories, net 6,426,429 6,737,848 
Other current assets 2,351,708 3,466,541 
Total current assets 63,626,211 68,684,845 
Property and equipment, net 539,019 528,882 
Intangible assets, net 20,370,330 21,444,545 
Deferred tax assets, net 87,210 87,210 
Other assets 2,809,306 2,486,830 
Total assets $87,432,076 $93,232,312 
LIABILITIES AND EQUITY 
Current liabilities: 
Accounts payable $8,447,429 $8,979,929 
Other current liabilities 7,070,860 8,714,814 
Total current liabilities 15,518,289 17,694,743 
Revolving line of credit 12,000,000 9,800,000 
Other long-term liabilities 1,969,174 1,815,968 
Total liabilities 29,487,463 29,310,711 
Commitments and contingencies 
Equity: 
Shareholders’ equity: 
Common stock—no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 51,235,612 52,410,941 
Retained earnings 6,966,252 11,709,222 
Total shareholders’ equity 58,201,864 64,120,163 
Noncontrolling interests (257,251)(198,562)
Total equity 57,944,613 63,921,601 
Total liabilities and equity $87,432,076 $93,232,312 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. 
1

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations and Comprehensive Income (loss)
(Unaudited)

Three months ended September 30, Nine months ended September 30, 
2018201720182017
Net revenues $8,492,530 $11,196,961 $27,243,859 $29,500,843 
Costs and expenses: 
Cost of products sold 1,460,463 2,166,353 4,511,743 5,216,776 
Selling and marketing 4,803,112 6,226,438 14,549,873 16,174,391 
Research and development 1,306,055 943,162 4,631,384 2,921,951 
General and administrative 2,067,981 2,090,785 6,732,485 6,554,158 
Amortization 661,802 609,572 1,946,457 1,811,589 
Total costs and expenses 10,299,413 12,036,310 32,371,942 32,678,865 
Operating income (loss) (1,806,883)(839,349)(5,128,083)(3,178,022)
Interest income 166,220 94,833 398,420 216,849 
Interest expense (19,199)(8,902)(59,520)(70,646)
Income (loss) before income taxes (1,659,862)(753,418)(4,789,183)(3,031,819)
Income tax (expense) benefit (4,159)(3,822)(12,477)(4,196,192)
Net income (loss) (1,664,021)(757,240)(4,801,660)(7,228,011)
Net loss at subsidiary attributable to noncontrolling interests 20,977 14,209 58,689 49,923 
Net income (loss) attributable to common shareholders $(1,643,044)$(743,031)$(4,742,971)$(7,178,088)
Earnings (loss) per share attributable to common shareholders 
- basic $(0.11)$(0.05)$(0.30)$(0.45)
- diluted $(0.11)$(0.05)$(0.30)$(0.45)
Weighted-average shares outstanding 
- basic 15,573,108 15,867,159 15,645,230 15,973,737 
- diluted 15,573,108 15,867,159 15,645,230 15,973,737 
Comprehensive income (loss) attributable to common shareholders (1,643,044)(743,031)(4,742,971)(7,178,088)
Net loss at subsidiary attributable to noncontrolling interests 20,977 14,209 58,689 49,923 
Total comprehensive income (loss) $(1,664,021)$(757,240)$(4,801,660)$(7,228,011)
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

2

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine months ended September 30, 
20182017
Cash flows from operating activities: 
Net income (loss) $(4,801,660)$(7,228,011)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: 
Depreciation and amortization expense 2,108,051 1,974,194 
Deferred tax expense — 4,293,963 
Share-based compensation 1,005,239 849,198 
Excess tax (benefit) expense derived from exercise of stock options — (91,109)
Noncash interest expense 44,117 60,708 
Noncash investment gains (131,652)(48,084)
Net changes in assets and liabilities affecting operating activities: 
Accounts receivable 1,339,974 124,748 
Inventories 311,419 (485,739)
Other current assets and other assets 966,817 (428,176)
Accounts payable and other current liabilities (1,595,243)640,453 
Other long-term liabilities 142,486 239,703 
Net cash provided by (used in) operating activities (610,452)(98,152)
Cash flows from investing activities: 
Additions to property and equipment (171,731)(172,899)
Purchases of marketable securities (20,851,951)(2,029,414)
Proceeds from sale of marketable securities 16,122,376 9,644,592 
Additions to intangible assets (1,411,710)(841,647)
Net cash (used in) provided by investing activities (6,313,016)6,600,632 
Cash flows from financing activities: 
Borrowings on line of credit 36,000,000 14,700,000 
Repayments on line of credit (33,800,000)(10,800,000)
Proceeds from sales of common stock, net of offering costs 200,909 — 
Payments of deferred offering costs (248,108)— 
Repurchase of common shares (2,382,968)(2,893,857)
Net cash provided by (used in) financing activities (230,167)1,006,143 
Net increase (decrease) in cash and cash equivalents (7,153,635)7,508,623 
Cash and cash equivalents at beginning of period $45,412,868 34,510,330 
Cash and cash equivalents at end of period $38,259,233 $42,018,953 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

3

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statement of Equity
(Unaudited)

Noncontrolling interests 
Common stock Retained earnings Total equity 
Shares Amount 
Balance, December 31, 2017 15,723,075 $52,410,941 $11,709,222 $(198,562)$63,921,601 
Proceeds from sales of common stock, net of offering costs 30,704 200,909 — — 200,909 
Share-based compensation 167,734 1,005,239 — — 1,005,239 
Repurchase of common shares (365,648)(2,381,477)— — (2,381,477)
Net loss — $— $(4,742,971)$(58,689)$(4,801,660)
Balance, September 30, 201815,555,865 $51,235,612 $6,966,251 $(257,251)$57,944,612 
See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

4

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(1) ORGANIZATION AND BASIS OF PRESENTATION
Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.
Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company’s products are manufactured by third parties, which are overseen by Cumberland’s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2017 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2018, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the “SEC”), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Annual Report on Form 10-K”). The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.
Total comprehensive income (loss) consisted solely of net income (loss) for the three and nine months ended September 30, 2018 and 2017.
Adoption of Revenue Recognition Accounting Standard
Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board’s (“FASB”) amended guidance in the form of Accounting Standards Update (“ASU”) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.
Net Product Revenue
Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company’s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments.
Sales Rebates and Discounts
The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.
Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company’s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a
5

wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company’s estimate of the rebate that may be claimed.
Sales Returns
Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company’s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.
Recent Accounting Guidance
Recent Adopted Accounting Pronouncements
In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard.
The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018. As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue.
In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows: Restricted Cash.” This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the “beginning-of-period” and “end-of-period” total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.
In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.” The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.
Recent Accounting Pronouncements - Not Yet Adopted
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.
In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-02, “Leases.” The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements
6

and disclosures. The Company’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023. The adoption of the new lease standard will result in the Company recording ROU assets and lease liabilities for these leases.
Accounting Policies:
Use of Estimates
In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.
Operating Segments
The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers. 
(2) MARKETABLE SECURITIES
The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (“SBA”) loan pools, and corporate bonds. At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time. As of September 30, 2018 and December 31, 2017, the marketable securities are comprised solely of trading securities. Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income (loss).
The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:
Level 1 - Quoted prices for identical instruments in active markets.
Level 2 - Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.
Level 3 -  Significant inputs to the valuation model are unobservable.
The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment. The Company has no marketable securities in which the fair value is determined based on Level 3 measurements. The level of management judgment required in evaluating fair value for Level 1 investments is minimal. Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as
7

derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices). There were no transfers of assets between levels within the fair value hierarchy. 
The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:
September 30, 2018 December 31, 2017 
Level 1 Level 2 Total Level 1 Level 2 Total 
U.S. Treasury notes and bonds $5,005,631 $— $5,005,631 $— $— $— 
U.S. Agency issued mortgage-backed securities – variable rate — — — — 3,539,102 3,539,102 
U.S. Agency notes and bonds – fixed rate — — — — 198,293 198,293 
Corporate bonds — 2,506,006 2,506,006 — — — 
SBA loan pools – variable rate — — — — 935,081 935,081 
Short-term cash investments — 2,022,066 2,022,066 — — — 
Total fair value of marketable securities $5,005,631 $4,528,072 $9,533,703 $— $4,672,476 $4,672,476 


(3) EARNINGS (LOSS) PER SHARE
The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2018 and 2017:
Three months ended September 30, 
20182017
Numerator: 
Net income (loss) attributable to common shareholders $(1,643,044)$(743,031)
Denominator: 
Weighted-average shares outstanding – basic 15,573,108 15,867,159 
Dilutive effect of other securities — — 
Weighted-average shares outstanding – diluted 15,573,108 15,867,159 
Nine months ended September 30, 
20182017
Numerator: 
Net income (loss) attributable to common shareholders $(4,742,971)$(7,178,088)
Denominator: 
Weighted-average shares outstanding – basic 15,645,230 15,973,737 
Dilutive effect of other securities — — 
Weighted-average shares outstanding – diluted 15,645,230 15,973,737 

As of September 30, 2018 and 2017, restricted stock awards and options to purchase 18,325 and 14,175 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.

8

(4) REVENUES
Product Revenues
The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements. See further discussion in Note 1. 
The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2018 and 2017:
Three months ended September 30, Nine months ended September 30, 
2018201720182017
Products: 
Acetadote $1,122,544 $1,342,457 $3,238,284 $4,331,675 
Omeclamox-Pak 278,017 190,835 509,358 1,213,635 
Kristalose 3,017,803 2,749,966 9,490,901 8,037,994 
Vaprisol (67,436)385,541 1,712,353 1,346,793 
Caldolor 1,318,109 896,640 3,458,881 2,762,790 
Ethyol 2,593,830 2,566,611 7,659,594 8,325,254 
Totect 45,249 2,916,425 727,211 2,916,425 
Other 184,414 148,486 447,277 566,277 
Total net revenues $8,492,530 $11,196,961 $27,243,859 $29,500,843 

Other Revenues
The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements. 

(5) INVENTORIES
The Company works closely with third parties to manufacture and package finished goods for sale. Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.
The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value. At September 30, 2018 and December 31, 2017, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.2 million, respectively.
In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (“API”) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at September 30, 2018 and December 31, 2017.

9

As of September 30, 2018 and December 31, 2017, net inventory consisted of the following:
September 30, 2018 December 31, 2017 
Raw materials and work in process $2,510,870 $3,156,002 
Consigned inventory 423,987 249,964 
Finished goods 3,491,572 3,331,882 
Total $6,426,429 $6,737,848 

(6) SHAREHOLDERS’ EQUITY AND DEBT
Share Repurchases
The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2016, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. During the nine months ended September 30, 2018 and September 30, 2017, the Company repurchased 365,648 shares and 438,715 shares, respectively, of common stock for approximately $2.4 million and $2.9 million, respectively.
Share Sale
In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. During the nine months ended September 30, 2018, the Company issued 30,704 shares of common stock for gross proceeds of $0.2 million as part of its At-The-Market (“ATM”) sales agreement with B. Riley FBR.
Restricted Share Grants
During the nine months ended September 30, 2018, and September 30, 2017, the Company issued 233,330 shares and 233,525 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).
Debt Agreement
On October 17, 2018, the Company entered into a second amendment (“Second Amendment”) to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (“Pinnacle Agreement”). The Second Amendment increases the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20 million. Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes. The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12 million with the ability to increase the principal amount available for borrowing up to $20 million, upon the satisfaction of certain conditions. The Second Amendment does not affect the term of the Pinnacle Agreement, which has a three year term expiring on July 31, 2020. The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had $12.0 million in borrowings under the Pinnacle Agreement at September 30, 2018 and $9.8 million at December 31, 2018.

The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (resulting in an interest rate of 4.0% at September 30, 2018). In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly. Borrowings under the line of credit are collateralized by substantially all of our assets.
Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis. On August 14, 2018 the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment. The Company was in compliance with the Tangible Capital Ratio covenant as of September 30, 2018. 

10

(7) INCOME TAXES
On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (“the Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (“AMT”) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.
The SEC staff issued Staff Accounting Bulletin (“SAB”) 118, providing guidance on applying the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements. If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.
In connection with our analysis of the impact of the Tax Act, we have a net tax benefit of $0.1 million as of September 30, 2018. This net tax benefit consists entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. The Company does not expect to record further amounts related to the Tax Act, but will continue to evaluate additional Internal Revenue Service guidance as it is released. The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.

(8) COLLABORATIVE AGREEMENTS
Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, Collaborative Agreements. The agreements do not specifically designate each party’s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).

(9) EVENT SUBSEQUENT TO THE BALANCE SHEET DATE
On November 6, 2018, Cumberland announced the acquisition of VIBATIV® (telavancin injection) from Theravance Biopharma U.S., Inc and Theravance Biopharma Ireland Limited (collectively, "Theravance Biopharma"). The financial terms include a $20 million payment to Theravance Biopharma upon closing, a $5 million additional payment in  early 2019 and tiered royalties up to 20% on future U.S. net product sales. The acquisition closed on November 12, 2018.

Cumberland has a Revolving Credit Loan with Pinnacle Bank that had an initial availability of up to $12 million with the ability to increase the principal amount available for borrowing up to $20 million. On October 17, 2018, Cumberland and Pinnacle Bank increased the maximum principal available for borrowing to $20 million.  The $12 million outstanding under the Revolving Credit loan was repaid during October 2018 and the Revolving Credit Loan was then used to fund the $20 million  payment for the VIBATIV acquisition.

The supplemental pro forma financial information that reflects revenue and earnings for VIBATIV is not yet being provided as the initial accounting for the business combination is not yet available to the Company as of the issuance of these financial statements. The Company will provide the supplemental pro forma financial information as it becomes available.

11

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion contains certain forward-looking statements which reflect management’s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that our actual results may differ significantly from the results we discuss in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital required to finance the business model; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; and management of our growth and integration of our acquisitions. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled “Risk Factors” and “Special Note Regarding Forward-Looking Statements” of our Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Annual Report on Form 10-K”). We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management’s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.


12

OVERVIEW

Our Business

Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address unmet or poorly met medical needs. We promote our approved products through our hospital and gastroenterology sales forces in the United States and are establishing a network of international partners to bring our products to patients in their countries.

Our portfolio of FDA approved brands includes:

•  Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning;

•  Caldolor® (ibuprofen) Injection, for the treatment of pain and fever;

• Kristalose® (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and    acute constipation;

• Omeclamox®-Pak, (omeprazole, clarithromycin and amoxicillin) for the treatment of    Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;

• Vaprisol® (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with    euvolemic and hypervolemic hyponatremia;

• Ethyol® (amifostine) Injection, for the reduction of xerostomia (dry mouth) in patients undergoing    post-operative radiation treatment for head and neck cancer and the renal toxicity associated with the    administration of cisplatin in patients with advanced ovarian cancer; and

• Totect® (dexrazoxane hydrochloride) Injection, for emergency oncology intervention, to treat the    toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the    bloodstream into the patient’s tissues).

• Vibativ® • (telavancin) Injection, for the treatment of certain serious bacterial infections including   hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and   skin structure infections.

Our pipeline of product candidates includes:

• Hepatoren® (ifetroban) Injection, a Phase II candidate for the treatment of critically ill patients    suffering from liver and kidney failure associated with hepatorenal syndrome ("HRS");

• Boxaban® (ifetroban) Oral Capsules, a Phase II candidate for the treatment of asthma patients with    aspirin exacerbated respiratory disease ("AERD");

• Vasculan® (ifetroban) Oral Capsules, a Phase II candidate for the treatment of patients with the    systemic sclerosis ("SSc") form of autoimmune disease;

• Portaban® (ifetroban) Injection and Oral Capsules, a Phase II candidate for the treatment of patients    with portal hypertension associated with liver disease; and

• RediTrexTM (methotrexate) Injection, an approval submission candidate for the treatment of active    rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as severe disabling psoriasis.


13



We have both product development and commercial capabilities, and believe we can leverage our existing infrastructure to support our expected growth. Cumberland's management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion opportunities. Cumberland's product development team creates proprietary product formulations, manages our clinical studies, prepares all regulatory submissions, maintains product approvals and manages our medical call center. The Company's quality and manufacturing professionals oversee the manufacture, packaging, release, and shipment of our products. Our marketing and sales professionals are responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.

Growth Strategy

Our growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently market eight FDA approved brands for sale in the United States. Through our international partners, we are working to bring our products to patients in their countries. We also look for opportunities to expand our products into additional patient populations through clinical trials, new indications, and select investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates to address unmet medical needs. Further, we are supplementing these activities with the pipeline drug development activities at Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary. Specifically, we are seeking long term sustainable growth by executing the following plans:

•Support and expand the use of our marketed products. We continue to evaluate our products following their FDA approval to determine if further clinical work could expand their potential markets. We will continue to explore opportunities for label expansion to bring our products to new patient populations. The Caldolor pediatric approval reflects our successful implementation of this strategy.

•Selectively add complementary brands. In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA approved drugs as well as late-stage development product candidates that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, with attractive financial profiles, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisitions of the product rights to Ethyol and RediTrex for the U.S. represent recent examples of our execution of this strategy.

•Progress clinical pipeline and incubate future product opportunities at CET. We believe it is important to build a pipeline of innovative new product opportunities. Our ifetroban Phase II development programs which emerged from CET represent the implementation of this strategy. At CET, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities. CET partners with universities and other research organizations to develop promising, early-stage product candidates. Cumberland has the opportunity to negotiate rights to further develop and commercialize these candidates in the U.S and other markets.

•Leverage our infrastructure through co-promotion partnerships. We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can accentuate our operational effectiveness and maximize the opportunity for our brands. Our recent co-promotion partnership with Poly Pharmaceuticals, Inc. allows us to expand current promotional support for Kristalose across the United States.

•Continue to build the international contribution to our business. We have established our own commercial capabilities, including two sales divisions to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to expand our network of international partners and continue to support our partners’ registration and commercialization efforts in their respective territories.

14

•Continue to manage our operations with financial discipline. We continually work to manage our expenses in line with our revenues with the goal of delivering positive cash flow from operations. We remain in a favorable financial position, with high margins, and a strong balance sheet.

Cumberland was incorporated in 1999 and has been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common stock and listing on the NASDAQ exchange. Our website address is www.cumberlandpharma.com.

We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all other material press releases, filings and amendments to those reports as soon as reasonably practicable after their filing with the SEC. These filings are also available to the public at www.sec.gov.


RECENT DEVELOPMENTS

New Product Acquisition

On November 6, 2018, the Company announced the acquisition of Vibativ® (telavancin) from Theravance Biopharma. Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

Under the terms of the agreement, which closed on November 12, 2018, Cumberland assumed full responsibility for the product including its marketing, distribution, manufacturing, and regulatory activities. Cumberland will support Vibativ in the U.S. through its established hospital sales organization. The Company expects to selectively expand its sales force, medical science liaison and corporate teams to ensure the needed support of Vibativ as well as its oncology and acute care brands.

The financial terms include a $20 million payment to Theravance Biopharma upon closing, a $5 million additional payment in early 2019, and tiered royalties of up to 20% on future U.S. net product sales. Cumberland has a Revolving Credit Loan with Pinnacle Bank that had an initial availability of up to $12 million with the ability to increase the principal amount available for borrowing up to $20 million. On October 17, 2018, Cumberland and Pinnacle Bank increased the  maximum principal available for borrowing to $20 million which was used to fund the initial payment for the Vibativ acquisition.  


Caldolor

In February 2018, we completed and filed the application for FDA approval of our Next Generation Caldolor product featuring an improved package and formulation. In April 2018, the FDA determined that the application was complete and notified us of their acceptance for review. On August 2, 2018, we received a complete response from the FDA outlining the additional information needed for the application’s approval. The requests were for additional quality and nonclinical data. We held a teleconference with the FDA to discuss their additional requirements. On September 26, 2018, the Company submitted an amendment to our application containing additional quality and nonclinical data. We now await the FDA's response and approval decision and prepare for the manufacture and launch of this new Caldolor product.

RediTrex Approval Submission

During November 2018, we completed the submission and filed with the FDA an application for the approval of our methotrexate product line which is designed for treating patients with arthritis and psoriasis. This filing follows two meetings held with the FDA to discuss the approval pathway and requirements for the submission. We now await FDA’s determination  of acceptance of the submission for their review. We remitted a payment of $1.3 million to the FDA for the PDUFA Application Fee associated with the methotrexate product line application.  

New Clinical Data Published

In September 2018 the Company and Clinigen, announced a new publication in Lung Cancer: Targets and Therapy of a contemporary retrospective series showing that subcutaneous amifostine administered before radiotherapy postponed the onset of acute esophagitis in stage 3 small cell lung cancer patients treated with concomitant doublet chemotherapy and
15

hyperfractionated radiotherapy. Cumberland markets branded amifostine in the U.S territory under the name Ethyol on behalf of Clinigen who is the market authorization holder and owner of global rights.

Cumberland also recently announced two favorable Caldolor study publications, adding to the growing library of literature supporting the brand. A study at The Ohio State Wexner Medical Center, published in the journal Frontiers in Surgery, reveals more effective pain control and opioid-sparing activity with Caldolor when compared to ketorolac in patients undergoing arthroscopic knee surgery.

Additionaly, a clinical trial conducted at Tufts University School of Dental Medicine and published online in the Journal of Oral and Maxillofacial Surgery, concluded that preemptive analgesia with Caldolor (IV ibuprofen) is more effective than Ofirmev® (IV acetaminophen) in reducing post-surgical pain and opioid use.

Ifetroban Phase II Studies

During the third quarter, we completed study enrollment for Portaban - the Company’s Portal Hypertension clinical program. Thirty patients were enrolled in a randomized, double-blind, placebo-controlled pilot study to assess ifetroban for the treatment of portal hypertension in cirrhotic patients.

This study was primarily designed to evaluate the safety of ifetroban treatment in this population and was not powered for any efficacy measurement. An initial review of the data from the study shows ifetroban was safe and well tolerated with no unexpected safety findings. We also measured hepatic venous pressure. Patients enrolled had a greater degree of variability than expected in their hepatic venous pressure gradient, therefore no definitive conclusions could be made on the impact of ifetroban on modulating that gradient. A full analysis of the data to include biomarkers and exploratory endpoints is ongoing. We will now await results from our other Phase II ifetroban studies before deciding on the best path for approval of our first new chemical entity.

We also continued to advance our Vasculan and Boxaban clinical pipeline programs, with patient enrollment progressing in each of those Phase II studies.

New CET Small Business Grant Award

At CET, we are working with a select group of academic research institutions located in the mid-south region of the U.S. These relationships enable CET to identify therapeutic compounds addressing poorly met medical needs and partner with university-based researchers to advance their scientific discoveries through pre-clinical development towards the market. CET contributes product design, development, and other support services to help our collaborators bridge the gap between discovery and clinical investigation.

In September 2018, CET announced that the U.S. National Cancer Institute awarded $2 million in support of a joint research program involving Cumberland Pharmaceuticals Inc., CET and researchers at Vanderbilt University. This Phase II grant is awarded under the Small Business Innovation Research funding mechanism and follows successful completion of an initial Phase I award.

The objective of the collaborative research program is to further develop a novel small molecule radiosensitizing agent for the treatment of certain lung cancers. By enhancing the cancer’s sensitivity to radiation therapy, this technology addresses a significant medical need of improving clinical outcomes for these oncology patients.

New Board Member

Effective September 19, 2018, the Company appointed Joseph C. Galante, American music industry executive, as its newest member of its Board of Directors. Mr. Galante is the former Chairman of Sony Music in Nashville and the Former President of RCA Records in New York City. Mr. Galante joins as the Company's seventh "independent director" as defined under applicable SEC and NASDAQ rules and he serves on the Company's Audit and Compensation Committees.

GEL Omeclamox-Pak Agreement

In March 2018, we reached an agreement with Gastro-Entero-Logic LLC, ("GEL") to acquire the assets associated with Omeclamox-Pak including the product’s FDA approved New Drug Application, trademarks, and other assets. Under the terms of the agreement, we will no longer be obligated to provide GEL with royalties or fees for overseeing the product’s
16

manufacturing. As part of this transaction, we will become responsible for maintaining the FDA approval and for overseeing the product’s packaging. The closing of this agreement is pending.

New Hospital Product Candidate

Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol reducing agent for use in the hospital setting. During 2017, we completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA and, as a result, a Phase II study has been initiated.

COMPETITION

The pharmaceutical industry is characterized by intense competition and rapid innovation. Our continued success in developing and commercializing pharmaceutical products will depend, in part, upon our ability to compete against existing and future products in our target markets. For more information see "Business - Competition" in our 2017 Annual Report on Form 10-K which is incorporated by reference and has been updated as follows:

Totect®

Totect is our patented, branded dexrazoxane injection product indicated for the treatment of the extravasation associated with anthracycline chemotherapy. We have an exclusive license to the product which includes patent number 6,727,253 which is FDA Orange Book listed and has a term until March 13, 2020. Pfizer Inc.’s Zinecard® brand is a dexrazoxane product with FDA approval for a different indication - the cardiac complications associated with certain chemotherapeutic agents. Mylan, Gland Pharma Ltd and West-Ward Pharmaceuticals Corp appear to have previously received FDA approval for a generic dexrazoxane with the Zinecard cardiac protection indication. When we launched Totect, the FDA reported a national dexrazoxane shortage with both the Pfizer and Mylan products unavailable.

Following our launch, supplies of dexrazoxane became available from Mylan, Pfizer, and two approved generic suppliers, all with labeling for the cardiac indication. Totect is the only dexrazoxane available in the U.S. FDA approved for the extravasation indication.


CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES
Please see a discussion of our critical accounting policies and significant judgments and estimates in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2017 Annual Report on Form 10-K.
Accounting Estimates and Judgments
The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, fair value of marketable securities, inventories, provision for income taxes, share-based compensation, research and development expenses and intangible assets.

17

RESULTS OF OPERATIONS
Three months ended September 30, 2018 compared to the three months ended September 30, 2017 
The following table presents the unaudited interim statements of operations for the three months ended September 30, 2018 and 2017:
Three months ended September 30, 
20182017Change 
Net revenues $8,492,530 $11,196,961 $(2,704,431)
Costs and expenses: 
Cost of products sold 1,460,463 2,166,353 (705,890)
Selling and marketing 4,803,112 6,226,438 (1,423,326)
Research and development 1,306,055 943,162 362,893 
General and administrative 2,067,981 2,090,785 (22,804)
Amortization 661,802 609,572 52,230 
Total costs and expenses 10,299,413 12,036,310 (1,736,897)
Operating income (loss) (1,806,883)(839,349)(967,534)
Interest income 166,220 94,833 71,387 
Interest expense (19,199)(8,902)(10,297)
Income (loss) before income taxes (1,659,862)(753,418)(906,444)
Income tax (expense) benefit (4,159)(3,822)(337)
Net income (loss) $(1,664,021)$(757,240)$(906,781)

The following table summarizes net revenues by product for the periods presented:
Three months ended September 30, 
20182017Change 
Products: 
Acetadote $1,122,544 $1,342,457 $(219,913)
Omeclamox-Pak 278,017 190,835 87,182 
Kristalose 3,017,803 2,749,966 267,837 
Vaprisol (67,436)385,541 (452,977)
Caldolor 1,318,109 896,640 421,469 
Ethyol 2,593,830 2,566,611 27,219 
Totect 45,249 2,916,425 (2,871,176)
Other 184,414 148,486 35,928 
Total net revenues $8,492,530 $11,196,961 $(2,704,431)

Net revenues. Net revenues for the three months ended September 30, 2018 were $8.5 million compared to $11.2 million for the three months ended September 30, 2017, representing a decrease of $2.7 million, or 24%. The decrease is due primarily to a decrease in Totect product sales volume compared to the prior year period. We began shipments of Totect during a national shortage of dexrazoxane, resulting in strong initial demand for the product. Following our launch, supplies of dexrazoxane became available from competing suppliers, all with labeling for the cardiac indication. As detailed in the table above, four of our seven marketed products experienced increases in net revenue during the quarter: Omeclamox-Pak, Kristalose, Caldolor, and Ethyol.
Vaprisol revenue experienced a decrease of $0.5 million during the third quarter of 2018 when compared to the prior year period due to lower sales volumes and higher returns of expired product. Sales of the product surged during the second quarter of 2018 due to shipments of newly arrived inventory following a period of time when there were limited supplies of the
18

product.  The negative net sales during the third quarter of 2018 resulted from higher than usual expired product returns in the period. 
Ethyol revenue remained consistent at $2.6 million for the three months ended September 30, 2018 and September 30, 2017. 
Kristalose revenue increased by $0.3 million or 9.7% during the third quarter of 2018 when compared to the prior year period. The product's net revenue was positively impacted by increased sales volumes and lower managed care and Medicaid rebates, resulting in improved net pricing for the product.
Omeclamox-Pak revenue increased $0.1 million primarily due to higher sales volumes as well as lower managed care and Medicaid rebates during the period.
Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a $0.2 million decrease in revenue from our Acetadote brand when compared to the prior year period as a result of increased competition.
Caldolor revenue increased $0.4 million for the three months ended September 30, 2018 primarily due to increased domestic and international sales revenue in the third quarter of 2018 compared to the third quarter of 2017. Domestic revenue of the brand grew due to improvement in deductions associated with shipment of the product.  
Cost of products sold. Cost of products sold for the third quarter of 2018 decreased $0.7 million compared to the prior year period as a result of lower sales. Cost of products sold, as a percentage of net revenues, improved to 17.2% during the three months ended September 30, 2018 compared to 19.3% during the three months ended September 30, 2017. This improvement in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, including the decrease in Totect sales, during the quarter compared to the prior year period.
Selling and marketing. Selling and marketing expense for the third quarter of 2018 decreased $1.4 million compared to the prior year period. This decrease is attributable to less royalties related to product sales during the third quarter of 2018.
Research and development. Research and development costs for the third quarter of 2018 were $1.3 million, compared to $0.9 million for the same period last year. A portion of our research and development costs is variable based on the number of trials, study sites and patients involved in the development of our new product candidates. The $0.4 million increase was the result of additional investments in our ongoing clinical and manufacturing initiatives associated with our pipeline products as well as increases in our FDA fees.
General and administrative. General and administrative expense for both the third quarter of 2018 and third quarter of 2017 remained consistent at $2.1 million.
Amortization. Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs. Amortization for the three months ended September 30, 2018 and the three months ended September 30, 2017  totaled approximately $0.7 million and $0.6 million, respectively.
Income taxes. Income tax expense for the three months ended September 30, 2018 was $4,159. As a percentage of income (loss) before income taxes, income tax expense was 0.3% for the three months ended September 30, 2018 compared to 0.5% for the three months ended September 30, 2017.
As of September 30, 2018, we have approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options in 2009 that have historically been used to significantly offset future income tax obligations. Since they were generated during 2009, we have utilized these net operating loss carryforwards to pay minimal income taxes. We will continue to pay minimal income taxes during 2018 and beyond, through the continued utilization of these net operating loss carryforwards, as we are able to achieve taxable income through our operations.
19

Nine months ended September 30, 2018 compared to the nine months ended September 30, 2017 
The following table presents the unaudited interim statements of operations for the nine months ended September 30, 2018 and 2017:
Nine months ended September 30, 
20182017Change 
Net revenues $27,243,859 $29,500,843 $(2,256,984)
Costs and expenses: 
Cost of products sold 4,511,743 5,216,776 (705,033)
Selling and marketing 14,549,873 16,174,391 (1,624,518)
Research and development 4,631,384 2,921,951 1,709,433 
General and administrative 6,732,485 6,554,158 178,327 
Amortization 1,946,457 1,811,589 134,868 
Total costs and expenses 32,371,942 32,678,865 (306,923)
Operating income (loss) (5,128,083)(3,178,022)(1,950,061)
Interest income 398,420 216,849 181,571 
Interest expense (59,520)(70,646)11,126 
Income (loss) before income taxes (4,789,183)(3,031,819)(1,757,364)
Income tax (expense) benefit (12,477)(4,196,192)4,183,715 
Net income (loss) $(4,801,660)$(7,228,011)$2,426,351 

The following table summarizes net revenues by product for the periods presented:
Nine months ended September 30, 
20182017Change 
Products: 
Acetadote $3,238,284 $4,331,675 $(1,093,391)
Omeclamox-Pak 509,358 1,213,635 (704,277)
Kristalose 9,490,901 8,037,994 1,452,907 
Vaprisol 1,712,353 1,346,793 365,560 
Caldolor 3,458,881 2,762,790 696,091 
Ethyol 7,659,594 8,325,254 (665,660)
Totect 727,211 2,916,425 (2,189,214)
Other 447,277 566,277 (119,000)
Total net revenues $27,243,859 $29,500,843 $(2,256,984)

Net revenues. Net revenues for the nine months ended September 30, 2018 were $27.2 million compared to $29.5 million for the nine months ended September 30, 2017, representing a decrease of $2.3 million, or 8%. The decrease is due primarily to a decrease in Totect product sales volume compared to the prior year period. We began shipments of Totect during a national shortage of dexrazoxane, resulting in strong initial demand for the product. Following our launch, supplies of dexrazoxane became available from competing suppliers, all with labeling for the cardiac indication. Totect is the only dexrazoxane available in the U.S. FDA approved for the extravasation indication. As detailed in the table above, three of our seven marketed products experienced increases in net revenue during the period: Kristalose, Vaprisol and Caldolor.
Kristalose revenue increased by 18.1% or $1.5 million during the nine months ended September 30, 2018. The product's net revenue was positively impacted by increased sales volumes and lower managed care and Medicaid rebates, resulting in improved net pricing for the product.   
Vaprisol revenue increased 27.1% or $0.4 million during the nine months ended September 30, 2018 compared to the prior year period primarily due to increased sales volume. Sales of the product surged during the second quarter of 2018 due to shipments
20

of newly arrived inventory following a period of time when there were limited supplies of the product. During April 2018, the Vaprisol supply issue was resolved as we received new shipments from our manufacturer.  
Caldolor revenue experienced an increase of $0.7 million during the nine months ended September 30, 2018 compared to the same period last year. This 25% increase in revenue in the nine months ended September 30, 2018 compared to the prior year period resulted from increased international shipments, an increase in international sales volumes and an increase in the products price. The year over year net revenue increase was partially offset by lower expired product sales returns which positively impacted the nine months ended September 30, 2017.
Acetadote revenue included net sales of our branded product and our share of net sales from our Authorized Generic. During the nine months ended September 30, 2018 the Acetadote net revenue decreased $1.1 million as a result of increased competition.
Ethyol revenue for the nine months ended September 30, 2018 was $7.7 million, which is a decrease of $0.7 million from the nine months ended September 30, 2017. The decrease was primarily the result of lower sales volume when compared to the prior year period, when wholesalers began to increase their inventory to meet hospital demand. The Ethyol shipments for the nine months ended September 30, 2018 are consistent with the shipments experienced during the second half of 2017.
Omeclamox-Pak revenue decreased $0.7 million during the nine months ended September 30, 2018 compared to the prior year. The decrease was primarily due to lower sales volumes as well as increases in expired product sales returns during the period.
Cost of products sold. Cost of products sold for the nine months ended September 30, 2018 and nine months ended September 30, 2017 were $4.5 million and $5.2 million, respectively. Cost of products sold, as a percentage of net revenues were 16.6% compared to 17.7% during the prior year. The decrease in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix during the period compared to the prior year.
Selling and marketing. Selling and marketing expenses for the nine months ended September 30, 2018 were $14.5 million, compared to $16.2 million for the prior year period, representing a decrease of approximately $1.6 million. This decrease was primarily attributable to less royalties related to product sales as well as lower promotional spending during the nine months ended September 30, 2018. Promotional spending was higher during 2017, primarily related to development of marketing materials.
Research and development. Research and development costs for the nine months ended September 30, 2018 were $4.6 million, compared to $2.9 million for the same period last year, representing an increase of approximately $1.7 million. A portion of our research and development costs is variable based on the number of trials, study sites and patients involved in the development of our product candidates. The increase was primarily the result of additional investment in our ongoing clinical initiatives associated with our pipeline products as well as increases in our FDA fees.
General and administrative. General and administrative expenses were $6.7 million for the nine months ended September 30, 2018, compared to $6.6 million during the same period last year. The $0.2 million increase from the prior year was primarily driven by an increase in compensation and benefits, including non-cash stock based compensation.
Amortization. Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs. Amortization for the nine months ended September 30, 2018 totaled approximately $1.9 million, which was an increase of $0.1 million over the prior year. The increase in amortization was attributable to additional product and license rights and capitalized patents.
Income taxes. Income tax expense for the nine months ended September 30, 2018 totaled $12,477 compared to $4,196,192 in the nine months ended September 30, 2017. As a percentage of income (loss) before income taxes, income taxes were 0.3% for the nine months ended September 30, 2018 compared to 138.4% for the nine months ended September 30, 2017. The effective tax rate for the nine months ended September 30, 2017 was primarily impacted by a valuation allowance of $1.0 million for our federal Orphan Drug and Research and Development tax credits as well as recording a full valuation allowance of $3.5 million for our remaining deferred tax assets. This additional non-cash valuation allowance impacted our effective tax rate during the nine months ended September 30, 2017.






21

LIQUIDITY AND CAPITAL RESOURCES
Working Capital
Our primary sources of liquidity are cash flows provided by our operations, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit, including its recent expansion to $20 million, will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future.
We invest a portion of our cash reserves in marketable securities including short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency notes and bonds, corporate bonds, and other marketable securities.  At September 30, 2018 and December 31, 2017, we had approximately $9.5 million and $4.7 million, respectively, invested in marketable securities.
The following table summarizes our liquidity and working capital as of September 30, 2018 and December 31, 2017:
September 30, 2018 December 31, 2017 
Cash and cash equivalents $38,259,233 $45,412,868 
Marketable securities 9,533,703 4,672,476 
Total cash, cash equivalents and marketable securities $47,792,936 $50,085,344 
Working capital (current assets less current liabilities) $48,107,922 $50,990,102 
Current ratio (multiple of current assets to current liabilities) 4.1 3.9 
Revolving line of credit availability $— $2,200,000 

As discussed below, our Revolving Credit Loan was expanded on October 17, 2018 from $12 million to $20 million. The $12 million outstanding under the Revolving Credit Loan was repaid during October 2018 and the Revolving Credit Loan was then used to fund the $20 million payment for the VIBATIV acquisition.  
The following table summarizes our net changes in cash and cash equivalents for the nine months ended September 30, 2018 and September 30, 2017:
Nine months ended September 30, 
20182017
Net cash provided by (used in): 
Operating activities $(610,452)$(98,152)
Investing activities (6,313,016)6,600,632 
Financing activities (230,167)1,006,143 
Net increase (decrease) in cash and cash equivalents $(7,153,635)$7,508,623 

The net $7.2 million decrease in cash and cash equivalents for the nine months ended September 30, 2018 was attributable to cash used in investing, financing and operating activities. Cash used in operating activities of $0.6 million was primarily impacted by the net loss for the period of $4.8 million. This use of cash was offset by changes in our working capital which provided net cash of $1.2 million, including net collections of accounts receivable of $1.3 million. The use of operating cash was further offset by the add back of non-cash expenses of depreciation and amortization and share-based compensation expense totaling $3.1 million. Cash used in investing activities included net cash invested in marketable securities of $4.7 million and additions to intangibles of $1.4 million. Our financing activities included $2.2 million in net cash provided by borrowings under our line of credit offset by $2.4 million in cash used to repurchase shares of our common stock.
The net $7.5 million increase in cash and cash equivalents for the nine months ended September 30, 2017 was attributable to cash provided by investing and financing activities offset by cash used in operating activities. Cash used by operating activities of $0.1 million was primarily impacted by a net loss for the period of $7.2 million. These uses of operating cash were offset by non-cash expenses of depreciation and amortization and share-based compensation expense totaling $2.8 million. Changes in our working capital used cash of $0.1 million, including an increase in accounts payable of $0.6 million offset by a decrease in accounts receivable of $0.1 million. Cash provided by investing activities included net proceeds from marketable securities of 
22

$7.6 million offset by additions to intangibles of $0.8 million. Our financing activities included $3.9 million in cash provided by borrowings under our line of credit and offset by $2.9 million in cash used to repurchase shares of our common stock.

Debt Agreement
On October 17, 2018, we entered into a second amendment ("Second Amendment") to amend the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (the "Pinnacle Agreement"). The Second Amendment increases the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20 million. We had $12 million in borrowings under that agreement at September 30, 2018. For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 6 to the accompanying unaudited condensed consolidated financial statements
Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis. On August 14, 2018 we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment. We were in compliance with the Tangible Capital Ratio covenant as of September 30, 2018 and expect to maintain compliance with this covenant in future periods.
OFF-BALANCE SHEET ARRANGEMENTS
During the nine months ended September 30, 2018 and 2017, we did not engage in any off-balance sheet arrangements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Risk
We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments.
We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. Based on the $9.5 million in marketable securities outstanding at September 30, 2018, a 1% decrease in the fair value of the securities would result in a reduction in pretax net income (loss) of $0.1 million.
Based on current interest rates, we do not believe we are exposed to significant downside risk related to change in interest on our investment accounts.
The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 2% to 3% (representing an interest rate of 4% at September 30, 2018). As of September 30, 2018, we had $12 million in borrowings outstanding under our revolving credit facility.
Exchange Rate Risk
While we operate primarily in the United States, we are exposed to foreign currency risk. Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations. We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice. Foreign currency exchange gains and losses were immaterial for the nine months ended September 30, 2018 and 2017. Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.
Item 4. Controls and Procedures
Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15-15(e) of the Exchange Act, as of September 30, 2018. Based on that evaluation, our CEO and CFO concluded that, as of September 30, 2018, our disclosure controls and procedures are considered effective to ensure that the information required to be disclosed by the Company in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's CEO and CFO, as appropriate, to allow for timely decisions regarding required disclosure.
23

During the three months ended September 30, 2018, there has not been any change in our internal control over financial reporting that has materially affected, or is likely to materially affect, our internal control over financial reporting.
24

PART II – OTHER INFORMATION
Item 1. Legal Proceedings
None.
Item 1A. Risk Factors
There have been no material changes to the information regarding risk factors that appears in the 2017 Annual Report on Form 10-K under the section titled "Risk Factors." 


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities
We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2016, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
The following table summarizes the activity, by month, during the three months ended September 30, 2018:
 
Period 
Total
Number of
Shares (or
Units)
Purchased (1)
Average
Price Paid
per Share
(or Unit)
Total Number of
Shares (or Units)
Purchased as Part
of Publicly
Announced Plans
or Programs
Maximum Number
(or Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs (1)
July 29,850 $6.18 29,850 $1,672,075 
August 21,676 (2) 5.92 21,676 1,543,814 
September 14,752 5.95 14,752 1,456,058 
Total 66,278 66,278 

(1) Shares repurchased by the Company under the share repurchase program established by our Board of Directors.

(2) Of this amount, 8,199 shares were repurchased directly through private purchases at the then-current fair market value of common stock.

25

Item 6. Exhibits
 
No. Description 
10.1 
31.1* 
31.2* 
32.1** 
101.INS* XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT. 
101.SCH* XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 
101.CAL* XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT 
101.DEF* XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 
101.LAB* XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 
101.PRE* XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 
* Filed herewith. 
** Furnished herewith. 

26

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Cumberland Pharmaceuticals Inc. 
Date:November 14, 2018By: /s/ Michael Bonner 
Michael Bonner 
Chief Financial Officer 

27
 EX-10.1 2 cpixq32018-exhibit101.htm EX-10.1 Document

FIRST AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT
THIS FIRST AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this “Amendment”) is entered into as of August 14, 2018, by and between CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation (the “Borrower”), and PINNACLE BANK, a Tennessee banking corporation (the “Lender”).
RECITALS:
A.The Borrower and the Lender entered into that certain Revolving Credit Loan Agreement (the “Loan Agreement”) dated as of July 31, 2017. Capitalized terms not otherwise defined therein have the same meaning as set forth in the Loan Agreement.
B. The Borrower and the Lender desire to amend the Loan Agreement as provided herein.
NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:
1. Section 6.7 of the Loan Agreement is hereby amended and restated as follows:
6.7 Funded Debt Ratio and Tangible Capital Ratio. Permit both (i) the Funded Debt Ratio of the Borrower as calculated for the Borrower and its Subsidiaries at the end of each fiscal quarter on a rolling four quarter basis to exceed 2.50 to 1.00, and (ii) the Funded Debt to Tangible Capital Ratio of the Borrower as calculated for the Borrower and its Subsidiaries to exceed forty percent (40%). For clarification, if the Borrower maintains compliance with either of the above required calculations, then the Borrower shall be in compliance with this Section 6.7 for the applicable period.
2. The following new definitions are hereby added to Section 9.1 of the Loan Agreement:
“Funded Debt to Tangible Capital Ratio” means the ratio, expressed as a percentage, of Funded Debt divided by Tangible Capital.
“Tangible Capital” means the amount equal to total shareholders’ equity, plus Funded Debt, less the value of intangible assets, all of the foregoing to be determined in accordance with the financial statements and reports provided to Lender, which are to be prepared in accordance with GAAP.
3. The Loan Agreement is not amended in any other respect.
4. The Borrower reaffirms the terms and provisions of the Loan Agreement, along with the other Loan Documents, and the Borrower agrees that such terms and provisions are valid and binding, enforceable in accordance with its terms and provisions, subject to no defense, counterclaim, or objection.
[signatures commence on following page]




ENTERED INTO as of the date first written above.
BORROWER: 
 
CUMBERLAND PHARMACEUTICALS INC. 
 

By:
/s/ A.J. Kazimi
A.J. Kazimi,
Chairman and Chief Executive Officer
 

LENDER: 
 
PINNACLE BANK 
 

By:
/s/ Tim Bewley
Tim Bewley,
Senior Vice President



[Signature Page to First Amendment to Revolving Credit Loan Agreement]


 EX-31.1 3 cpixq32018-exhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, A.J. Kazimi, certify that:
1
I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.;

2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
November 14, 2018By: /s/ A.J. Kazimi 
A.J. Kazimi 
Chief Executive Officer 
c.

 EX-31.2 4 cpixq32018-exhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Michael Bonner, certify that:
1
I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.;

2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
November 14, 2018By: /s/ Michael Bonner 
Michael Bonner 
Chief Financial Officer 
c.

 EX-32.1 5 cpixq32018-exhibit321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE AND
CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2018 of Cumberland Pharmaceuticals Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, A.J. Kazimi, Chief Executive Officer and Michael Bonner, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that:
1
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ A. J. Kazimi 
A.J. Kazimi 
Chief Executive Officer 
November 14, 2018
/s/ Michael Bonner 
Michael Bonner 
Chief Financial Officer 
November 14, 2018
 


 EX-101.SCH 6 cpix-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statement of Equity link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Organization and Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Organization and Basis of Presentation Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Earnings (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2111104 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 2312303 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2114105 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2315304 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - Inventories (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2118106 - Disclosure - Shareholders' Equity and Debt link:presentationLink link:calculationLink link:definitionLink 2419408 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details) link:presentationLink link:calculationLink link:definitionLink 2420409 - Disclosure - Shareholders' Equity and Debt (Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2121107 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2422410 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 2123108 - Disclosure - Collaborative Agreements link:presentationLink link:calculationLink link:definitionLink 2124109 - Disclosure - Event Subsequent to the Balance Sheet Date link:presentationLink link:calculationLink link:definitionLink 2425411 - Disclosure - Event Subsequent to the Balance Sheet Date (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cpix-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 cpix-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 cpix-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Common stock Common Stock [Member] Interest rate spread Debt Instrument, Interest Rate, Stated Percentage Range [Domain] Range [Domain] Inventory Disclosure [Abstract] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Expiration period Line of Credit Facility, Expiration Period Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Accounts payable Accounts Payable, Current Relationship to Entity [Domain] Relationship to Entity [Domain] Deferred tax assets, net Deferred Tax Assets, Net, Noncurrent Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Marketable securities Marketable Securities Current Fiscal Year End Date Current Fiscal Year End Date Restricted Stock Restricted Stock [Member] Equity Award [Domain] Equity Award [Domain] Additions to property and equipment Payments to Acquire Property, Plant, and Equipment Fair value of marketable securities, by type Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Noncash investment gains Unrealized Gain (Loss) on Investments Caldolor Caldolor [Member] Caldolor Finished goods Inventory, Finished Goods, Net of Reserves Line of Credit Facility [Table] Line of Credit Facility [Table] Common stock, shares outstanding (in shares) Balance, Beginning of Period (in shares) Balance, End of Period (in shares) Common Stock, Shares, Outstanding Other long-term liabilities Other Long Term Obligations, Excluding Current Portion Other Long Term Obligations, Excluding Current Portion Level 1 Fair Value, Inputs, Level 1 [Member] Repurchase of common shares Payments for Repurchase of Common Stock Inventory Inventory, Net, Items Net of Reserve Alternative [Abstract] Other current assets and other assets Increase (Decrease) in Other Operating Assets Lender Name [Axis] Lender Name [Axis] Property and equipment, net Property, Plant and Equipment, Net Debt Instrument [Axis] Debt Instrument [Axis] Costs and expenses: Costs and Expenses [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Second Amendment Second Amendment [Member] Second Amendment Selling and marketing Selling and Marketing Expense Operating income (loss) Operating Income (Loss) U.S. Agency issued mortgage-backed securities – variable rate Mortgage-backed Securities, Issued by Private Enterprises [Member] Statement [Table] Statement [Table] Inventories Increase (Decrease) in Inventories Net changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Subsequent Event Subsequent Event [Member] Investments, Debt and Equity Securities [Abstract] Consigned inventory Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross Proceeds from the sale of common stock, net of offering costs Stock Issued During Period, Value, New Issues Commitments and contingencies Commitments and Contingencies Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement of Stockholders' Equity [Abstract] Borrowings on line of credit Proceeds from (Repayments of) Lines of Credit Research and development Research and Development Expense Shareholders' Equity (Textual) [Abstract] Shareholders Equity (Textual) [Abstract] Shareholders Equity. Total liabilities Liabilities - basic (in dollars per share) Earnings Per Share, Basic - basic (in shares) Weighted-average shares outstanding – basic (in shares) Weighted Average Number of Shares Outstanding, Basic Net loss at subsidiary attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Intangible assets, net Finite-Lived Intangible Assets, Net Document Period End Date Document Period End Date Products: Products [Abstract] Products. Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Denominator: Denominator [Abstract] Denominator. Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Noncash interest expense Amortization of Debt Issuance Costs Interest income Investment Income, Interest Vaprisol Vaprisol [Member] Vaprisol Acetadote Acetadote [Member] Acetadote Financial Instruments [Domain] Financial Instruments [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Other Other Products [Member] Other Products Common stock—no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued ASSETS Assets [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Range [Axis] Range [Axis] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value EVENT SUBSEQUENT TO THE BALANCE SHEET DATE Subsequent Events [Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Cost of products sold Cost of Goods and Services Sold Director Director [Member] Document Fiscal Year Focus Document Fiscal Year Focus SHAREHOLDERS' EQUITY AND DEBT Stockholders' Equity Note Disclosure [Text Block] Net Revenues Revenues [Abstract] Total assets Assets Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Net income (loss) Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Title of Individual [Axis] Title of Individual [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Deferred tax expense Deferred Income Tax Expense (Benefit) Document Type Document Type Other assets Other Assets, Noncurrent Entity Emerging Growth Company Entity Emerging Growth Company Retained earnings Retained Earnings [Member] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Income Statement [Abstract] Proceeds from the sale of common stock, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues - diluted (in dollars per share) Earnings Per Share, Diluted SBA loan pools – variable rate LoanPoolsMember Total costs and expenses Costs and Expenses Amortization Amortization of Intangible Assets Line of credit, unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Number of operating segments Number of Operating Segments Use of Estimates Use of Estimates, Policy [Policy Text Block] Income tax (expense) benefit Income Tax Expense (Benefit) Line of credit, maximum borrowing capacity upon satisfaction of certain conditions Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions REVENUES Segment Reporting Disclosure [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Inventories, net Total Inventory, Net Total current assets Assets, Current Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Excess tax (benefit) expense derived from exercise of stock options Excess Tax Benefit from Share-based Compensation, Operating Activities Common stock available for purchase through restricted stock awards and options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Financial Position [Abstract] Revolving line of credit Long-term Line of Credit, Noncurrent MARKETABLE SECURITIES Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Corporate bonds Corporate Bond Securities [Member] Total current liabilities Liabilities, Current SunTrust Bank SunTrustBankMember General and administrative General and Administrative Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Reconciliation of numerator and denominator Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Share-based compensation Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Total liabilities and equity Liabilities and Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total equity Balance, Beginning of Period Balance, End of Period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Comprehensive income (loss) attributable to common shareholders Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Accounts receivable, net Accounts Receivable, Net, Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Line of Credit Line of Credit [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Equity Components [Axis] Equity Components [Axis] Restricted stock granted in period, shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Inventory Schedule of Inventory, Current [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Omeclamox-Pak Omeclamox-Pak [Member] Omeclamox-Pak Award Type [Axis] Award Type [Axis] Proceeds from sales of common stock, net of offering costs Proceeds from Issuance of Common Stock U.S. Agency notes and bonds – fixed rate Agency Securities [Member] Equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Recent Accounting Guidance New Accounting Pronouncements, Policy [Policy Text Block] - diluted (in shares) Weighted-average shares outstanding – diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Short-term cash investments Municipal Bonds [Member] ORGANIZATION AND BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities Common stock, shares issued (in shares) Common Stock, Shares, Issued Accounts payable and other current liabilities IncreaseDecreaseInCurrentOperatingLiabilities Reserve for potential obsolescence of products Inventory Valuation Reserves Summary of net revenue Revenue from External Customers by Products and Services [Table Text Block] Subsequent Events [Abstract] Pinnacle Bank Pinnacle Bank [Member] Pinnacle Bank Share-based compensation Share-based Compensation Payment to acquire business upon closing Payments to Acquire Businesses, Gross Common stock, par value (in dollars per share) Common Stock, No Par Value Net income (loss) attributable to common shareholders Net income (loss) attributable to common shareholders Net Income (Loss) Attributable to Parent Dilutive effect of other securities (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Noncontrolling interests Noncontrolling Interest [Member] Net loss at subsidiary attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Raw materials and work in process Inventory, Raw Materials, Net of Reserves Repayments on line of credit Repayments of Notes Payable Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Ethyol Ethyol [Member] Ethyol Accounts receivable Increase (Decrease) in Accounts Receivable Entity Small Business Entity Small Business Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Purchases of marketable securities Payments to Acquire Marketable Securities U.S. Treasury notes and bonds Us Treasury Notes And Bonds Securities Member [Member] Us Treasury Notes And Bonds Securities Member Entity Filer Category Entity Filer Category Additions to intangible assets Payments to Acquire Intangible Assets Repayments on revolving credit loan Repayments of Lines of Credit Repurchase of shares Repurchase of shares, value Stock Repurchased During Period, Value Income Tax Disclosure [Abstract] Restricted stock awards, vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Product and Service [Axis] Product and Service [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Depreciation and amortization expense Depreciation, Depletion and Amortization Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Statement [Line Items] Statement [Line Items] Marketable securities Debt Securities, Trading, and Equity Securities, FV-NI Equity and Debt [Abstract] Equity and Debt [Abstract] Other current assets Other Assets, Current Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Entity Registrant Name Entity Registrant Name Repurchase outstanding common shares Stock Repurchase Program, Authorized Amount Kristalose Kristalose [Member] Kristalose Current liabilities: Liabilities, Current [Abstract] Amendment Flag Amendment Flag Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Net revenues Net revenues Revenue from Contract with Customer, Excluding Assessed Tax Credit Facility [Domain] Credit Facility [Domain] INCOME TAXES Income Tax Disclosure [Text Block] Numerator: Numerator [Abstract] Numerator. Entity Central Index Key Entity Central Index Key Segment Reporting [Abstract] Operating Segments Segment Reporting, Policy [Policy Text Block] Payments of deferred offering costs Payments of Stock Issuance Costs Statement of Cash Flows [Abstract] Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Interest expense Interest Expense Shelf Registration, sale of corporate securities (up to) StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities Line of credit, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Common stock, shares authorized (in shares) Common Stock, Shares Authorized Earnings (loss) per share attributable to common shareholders Earnings Per Share [Abstract] Product and Service [Domain] Product and Service [Domain] Subsequent Event [Line Items] Subsequent Event [Line Items] Minimum Minimum [Member] Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Current assets: Assets, Current [Abstract] INVENTORIES Inventory Disclosure [Text Block] Share-based compensation (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Credit Facility [Axis] Credit Facility [Axis] Percentage of tiered royalty payments (up to) Tiered Royalty Payments, Percentage Tiered Royalty Payments, Percentage Total shareholders’ equity Stockholders' Equity Attributable to Parent EARNINGS (LOSS) PER SHARE Earnings Per Share [Text Block] Additional payment to acquire business Additional Payments to Acquire Businesses Additional Payments to Acquire Businesses COLLABORATIVE AGREEMENTS Collaborative Arrangement Disclosure [Text Block] Document and Entity Information [Abstract] Document and entity information. Other current liabilities Other Liabilities, Current VIBATIV VIBATIV [Member] VIBATIV Repurchase of shares (in shares) Repurchase of shares (in shares) Stock Repurchased During Period, Shares Equity Component [Domain] Equity Component [Domain] Maximum Maximum [Member] Totect Totect [Member] Totect Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] EX-101.PRE 10 cpix-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 cpix-20180930_htm.xml IDEA: XBRL DOCUMENT 0001087294 2018-01-01 2018-09-30 0001087294 2017-01-01 2017-09-30 0001087294 us-gaap:RevolvingCreditFacilityMember cpix:SecondAmendmentMember cpix:PinnacleBankMember us-gaap:SubsequentEventMember 2018-10-17 0001087294 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember 2017-07-31 0001087294 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember 2017-07-31 0001087294 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember 2017-07-31 0001087294 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:SunTrustBankMember 2018-09-30 0001087294 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember 2017-07-31 2017-07-31 0001087294 us-gaap:RestrictedStockMember us-gaap:DirectorMember 2018-01-01 2018-09-30 0001087294 cpix:VIBATIVMember us-gaap:SubsequentEventMember 2018-11-06 2018-11-06 0001087294 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember 2018-09-30 0001087294 2016-12-31 0001087294 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember cpix:PinnacleBankMember us-gaap:SubsequentEventMember 2018-10-01 2018-10-31 0001087294 2017-09-30 0001087294 us-gaap:CommonStockMember 2017-12-31 0001087294 us-gaap:RetainedEarningsMember 2017-12-31 0001087294 us-gaap:NoncontrollingInterestMember 2017-12-31 0001087294 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001087294 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001087294 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-09-30 0001087294 us-gaap:CommonStockMember 2018-09-30 0001087294 us-gaap:NoncontrollingInterestMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel1Member cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel2Member cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember 2018-09-30 0001087294 cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel1Member cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel2Member cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember 2017-12-31 0001087294 cpix:UsTreasuryNotesAndBondsSecuritiesMemberMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel1Member us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel2Member us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember 2018-09-30 0001087294 2018-11-09 0001087294 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel1Member us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel2Member us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember 2017-12-31 0001087294 us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel1Member us-gaap:AgencySecuritiesMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel2Member us-gaap:AgencySecuritiesMember 2018-09-30 0001087294 us-gaap:AgencySecuritiesMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel1Member us-gaap:AgencySecuritiesMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel2Member us-gaap:AgencySecuritiesMember 2017-12-31 0001087294 us-gaap:AgencySecuritiesMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2018-09-30 0001087294 us-gaap:CorporateBondSecuritiesMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateBondSecuritiesMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2017-12-31 0001087294 us-gaap:CorporateBondSecuritiesMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel1Member cpix:LoanPoolsMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel2Member cpix:LoanPoolsMember 2018-09-30 0001087294 cpix:LoanPoolsMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel1Member cpix:LoanPoolsMember 2017-12-31 0001087294 2018-09-30 0001087294 us-gaap:FairValueInputsLevel2Member cpix:LoanPoolsMember 2017-12-31 0001087294 cpix:LoanPoolsMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel1Member us-gaap:MunicipalBondsMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2018-09-30 0001087294 us-gaap:MunicipalBondsMember 2018-09-30 0001087294 us-gaap:FairValueInputsLevel1Member us-gaap:MunicipalBondsMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2017-12-31 0001087294 us-gaap:MunicipalBondsMember 2017-12-31 0001087294 us-gaap:FairValueInputsLevel1Member 2018-09-30 0001087294 us-gaap:FairValueInputsLevel2Member 2018-09-30 0001087294 2017-12-31 0001087294 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001087294 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001087294 cpix:AcetadoteMember 2018-07-01 2018-09-30 0001087294 cpix:AcetadoteMember 2017-07-01 2017-09-30 0001087294 cpix:AcetadoteMember 2018-01-01 2018-09-30 0001087294 cpix:AcetadoteMember 2017-01-01 2017-09-30 0001087294 cpix:OmeclamoxPakMember 2018-07-01 2018-09-30 0001087294 cpix:OmeclamoxPakMember 2017-07-01 2017-09-30 0001087294 cpix:OmeclamoxPakMember 2018-01-01 2018-09-30 0001087294 cpix:OmeclamoxPakMember 2017-01-01 2017-09-30 0001087294 cpix:KristaloseMember 2018-07-01 2018-09-30 0001087294 cpix:KristaloseMember 2017-07-01 2017-09-30 0001087294 cpix:KristaloseMember 2018-01-01 2018-09-30 0001087294 cpix:KristaloseMember 2017-01-01 2017-09-30 0001087294 cpix:VaprisolMember 2018-07-01 2018-09-30 0001087294 cpix:VaprisolMember 2017-07-01 2017-09-30 0001087294 cpix:VaprisolMember 2018-01-01 2018-09-30 0001087294 cpix:VaprisolMember 2017-01-01 2017-09-30 0001087294 cpix:CaldolorMember 2018-07-01 2018-09-30 0001087294 cpix:CaldolorMember 2017-07-01 2017-09-30 0001087294 2018-07-01 2018-09-30 0001087294 cpix:CaldolorMember 2018-01-01 2018-09-30 0001087294 cpix:CaldolorMember 2017-01-01 2017-09-30 0001087294 cpix:EthyolMember 2018-07-01 2018-09-30 0001087294 cpix:EthyolMember 2017-07-01 2017-09-30 0001087294 cpix:EthyolMember 2018-01-01 2018-09-30 0001087294 cpix:EthyolMember 2017-01-01 2017-09-30 0001087294 cpix:TotectMember 2018-07-01 2018-09-30 0001087294 cpix:TotectMember 2017-07-01 2017-09-30 0001087294 cpix:TotectMember 2018-01-01 2018-09-30 0001087294 cpix:TotectMember 2017-01-01 2017-09-30 0001087294 2017-07-01 2017-09-30 0001087294 cpix:OtherProductsMember 2018-07-01 2018-09-30 0001087294 cpix:OtherProductsMember 2017-07-01 2017-09-30 0001087294 cpix:OtherProductsMember 2018-01-01 2018-09-30 0001087294 cpix:OtherProductsMember 2017-01-01 2017-09-30 0001087294 2010-05-13 0001087294 2016-01-31 0001087294 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001087294 2017-11-01 2017-11-30 0001087294 us-gaap:RestrictedStockMember 2018-01-01 2018-09-30 0001087294 us-gaap:RestrictedStockMember 2017-01-01 2017-09-30 pure shares cpix:Segment iso4217:USD iso4217:USD shares Non-accelerated Filer 2018-09-30 2018 Q3 false false false --12-31 0001087294 0 0 100000000 100000000 15555865 15723075 15555865 15723075 P1Y P3Y 10-Q Cumberland Pharmaceuticals Inc. 15527623 38259233 45412868 9533703 4672476 7055138 8395112 6426429 6737848 2351708 3466541 63626211 68684845 539019 528882 20370330 21444545 87210 87210 2809306 2486830 87432076 93232312 8447429 8979929 7070860 8714814 15518289 17694743 12000000 9800000 1969174 1815968 29487463 29310711 51235612 52410941 6966252 11709222 58201864 64120163 -257251 -198562 57944613 63921601 87432076 93232312 8492530 11196961 27243859 29500843 1460463 2166353 4511743 5216776 4803112 6226438 14549873 16174391 1306055 943162 4631384 2921951 2067981 2090785 6732485 6554158 661802 609572 1946457 1811589 10299413 12036310 32371942 32678865 -1806883 -839349 -5128083 -3178022 166220 94833 398420 216849 19199 8902 59520 70646 -1659862 -753418 -4789183 -3031819 4159 3822 12477 4196192 -1664021 -757240 -4801660 -7228011 -20977 -14209 -58689 -49923 -1643044 -743031 -4742971 -7178088 -0.11 -0.05 -0.30 -0.45 -0.11 -0.05 -0.30 -0.45 15573108 15867159 15645230 15973737 15573108 15867159 15645230 15973737 -1643044 -743031 -4742971 -7178088 20977 14209 58689 49923 -1664021 -757240 -4801660 -7228011 -4801660 -7228011 2108051 1974194 0 4293963 1005239 849198 0 91109 44117 60708 131652 48084 -1339974 -124748 -311419 485739 -966817 428176 -1595243 640453 142486 239703 -610452 -98152 171731 172899 20851951 2029414 16122376 9644592 1411710 841647 -6313016 6600632 36000000 14700000 33800000 10800000 200909 0 248108 0 2382968 2893857 -230167 1006143 -7153635 7508623 45412868 34510330 38259233 42018953 15723075 52410941 11709222 -198562 63921601 30704 200909 200909 167734 1005239 1005239 365648 2381477 2381477 -4742971 -58689 -4801660 15555865 51235612 -257251 ORGANIZATION AND BASIS OF PRESENTATION<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company’s products are manufactured by third parties, which are overseen by Cumberland’s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2017 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2018, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the “SEC”), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Annual Report on Form 10-K”). The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Total comprehensive income (loss) consisted solely of net income (loss) for the three and nine months ended September 30, 2018 and 2017.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Adoption of Revenue Recognition Accounting Standard</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board’s (“FASB”) amended guidance in the form of Accounting Standards Update (“ASU”) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Net Product Revenue</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company’s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Sales Rebates and Discounts</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company’s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company’s estimate of the rebate that may be claimed.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Sales Returns</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company’s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Adopted Accounting Pronouncements </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018. As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows: Restricted Cash.” This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the “beginning-of-period” and “end-of-period” total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.” The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-02, “Leases.” The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> and disclosures. The Company’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023. The adoption of the new lease standard will result in the Company recording ROU assets and lease liabilities for these leases.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Policies:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;">Operating Segments</span></div>The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers. <div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Adoption of Revenue Recognition Accounting Standard</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board’s (“FASB”) amended guidance in the form of Accounting Standards Update (“ASU”) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Net Product Revenue</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company’s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Sales Rebates and Discounts</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company’s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company’s estimate of the rebate that may be claimed.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Sales Returns</span></div><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company’s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div> <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Adopted Accounting Pronouncements </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018. As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows: Restricted Cash.” This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the “beginning-of-period” and “end-of-period” total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.” The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.</span></div><div style="margin-top:5pt;margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-02, “Leases.” The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements</span></div> and disclosures. The Company’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023. The adoption of the new lease standard will result in the Company recording ROU assets and lease liabilities for these leases. <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.</span></div> Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers. 1 MARKETABLE SECURITIES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (“SBA”) loan pools, and corporate bonds. At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time. As of September 30, 2018 and December 31, 2017, the marketable securities are comprised solely of trading securities. Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Level 1 - Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Level 2 - Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Level 3 -  Significant inputs to the valuation model are unobservable.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment. The Company has no marketable securities in which the fair value is determined based on Level 3 measurements. The level of management judgment required in evaluating fair value for Level 1 investments is minimal. Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices). There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:11pt;line-height:120%;"> </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:27.368576%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018 </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017 </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,005,631 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,005,631 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency issued mortgage-backed securities – variable rate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,539,102 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,539,102 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency notes and bonds – fixed rate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">198,293 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">198,293 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,506,006 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,506,006 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">SBA loan pools – variable rate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">935,081 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">935,081 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,022,066 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,022,066 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable securities </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,005,631 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,528,072 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,533,703 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,672,476 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,672,476 </span></td></tr></table></div> <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561404%;"><tr><td style="width:1.0%;"/><td style="width:27.368576%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534214%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160059%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018 </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;height:15pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017 </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Treasury notes and bonds </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,005,631 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,005,631 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency issued mortgage-backed securities – variable rate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,539,102 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,539,102 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. Agency notes and bonds – fixed rate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">198,293 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">198,293 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate bonds </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,506,006 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,506,006 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">SBA loan pools – variable rate </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">935,081 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">935,081 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term cash investments </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,022,066 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Arial;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,022,066 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable securities </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">5,005,631 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,528,072 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,533,703 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,672,476 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,672,476 </span></td></tr></table></div> 5005631 0 5005631 0 0 0 0 0 0 0 3539102 3539102 0 0 0 0 198293 198293 198293 198293 0 2506006 2506006 0 0 0 0 0 0 0 0 0 0 935081 935081 0 2022066 2022066 0 0 0 5005631 4528072 9533703 0 4672476 4672476 EARNINGS (LOSS) PER SHARE<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2018 and 2017:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:63.102639%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.008798%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.155425%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,643,044)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(743,031)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding – basic </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,573,108 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,867,159 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding – diluted </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,573,108 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,867,159 </span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine months ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,742,971)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,178,088)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding – basic </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,645,230 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,973,737 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding – diluted </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,645,230 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,973,737 </span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of September 30, 2018 and 2017, restricted stock awards and options to purchase 18,325 and 14,175 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div> <div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2018 and 2017:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:63.102639%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:15.008798%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.155425%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:12pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:12pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,643,044)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(743,031)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding – basic </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,573,108 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,867,159 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding – diluted </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,573,108 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,867,159 </span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:13pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine months ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,742,971)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,178,088)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding – basic </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,645,230 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,973,737 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding – diluted </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,645,230 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">15,973,737 </span></td></tr></table></div> -1643044 -743031 15573108 15867159 0 0 15573108 15867159 -4742971 -7178088 15645230 15973737 0 0 15645230 15973737 18325 14175 REVENUES<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Product Revenues</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements. See further discussion in Note 1. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2018 and 2017:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.222222%;"><tr><td style="width:1.0%;"/><td style="width:35.293233%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.090226%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.852632%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285714%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551880%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.488722%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551880%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine months ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Products: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,122,544 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,342,457 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,238,284 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,331,675 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">278,017 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">190,835 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">509,358 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,213,635 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,017,803 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,749,966 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,490,901 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,037,994 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(67,436)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">385,541 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,712,353 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,346,793 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,318,109 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">896,640 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,458,881 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,762,790 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,593,830 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,566,611 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,659,594 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,325,254 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Totect </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">45,249 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,916,425 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">727,211 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,916,425 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">184,414 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">148,486 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">447,277 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">566,277 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,492,530 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,196,961 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,243,859 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29,500,843 </span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Other Revenues</span></div>The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements. <div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2018 and 2017:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.222222%;"><tr><td style="width:1.0%;"/><td style="width:35.293233%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.090226%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.852632%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285714%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551880%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.488722%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.551880%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.285714%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;height:14pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine months ended September 30, </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2017</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Products: </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,122,544 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,342,457 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,238,284 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">4,331,675 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">278,017 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">190,835 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">509,358 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,213,635 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,017,803 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,749,966 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">9,490,901 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,037,994 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">(67,436)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">385,541 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,712,353 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,346,793 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">1,318,109 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">896,640 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,458,881 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,762,790 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Ethyol </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,593,830 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,566,611 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">7,659,594 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,325,254 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Totect </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">45,249 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,916,425 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">727,211 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,916,425 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Other </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">184,414 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">148,486 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">447,277 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">566,277 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">8,492,530 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">11,196,961 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">27,243,859 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">29,500,843 </span></td></tr></table></div> 1122544 1342457 3238284 4331675 278017 190835 509358 1213635 3017803 2749966 9490901 8037994 -67436 385541 1712353 1346793 1318109 896640 3458881 2762790 2593830 2566611 7659594 8325254 45249 2916425 727211 2916425 184414 148486 447277 566277 8492530 11196961 27243859 29500843 INVENTORIES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company works closely with third parties to manufacture and package finished goods for sale. Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value. At September 30, 2018 and December 31, 2017, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.2 million, respectively. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (“API”) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at September 30, 2018 and December 31, 2017.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of September 30, 2018 and December 31, 2017, net inventory consisted of the following: </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:60.316716%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.475073%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.475073%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,510,870 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,156,002 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">423,987 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">249,964 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,491,572 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,331,882 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,426,429 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,737,848 </span></td></tr></table></div> 100000 200000 <div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">As of September 30, 2018 and December 31, 2017, net inventory consisted of the following: </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707602%;"><tr><td style="width:1.0%;"/><td style="width:60.316716%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:16.475073%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533138%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.475073%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2017 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">2,510,870 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,156,002 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">423,987 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">249,964 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,491,572 </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">3,331,882 </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">Total </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,426,429 </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:Times New Roman;color:#000000;background-color:rgb(255,255,255, 0.0);">6,737,848 </span></td></tr></table></div> 2510870 3156002 423987 249964 3491572 3331882 6426429 6737848 SHAREHOLDERS’ EQUITY AND DEBT<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Share Repurchases</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2016, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. During the nine months ended September 30, 2018 and September 30, 2017, the Company repurchased 365,648 shares and 438,715 shares, respectively, of common stock for approximately $2.4 million and $2.9 million, respectively. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Share Sale</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. During the nine months ended September 30, 2018, the Company issued 30,704 shares of common stock for gross proceeds of $0.2 million as part of its At-The-Market (“ATM”) sales agreement with B. Riley FBR.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Restricted Share Grants </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">During the nine months ended September 30, 2018, and September 30, 2017, the Company issued 233,330 shares and 233,525 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On October 17, 2018, the Company entered into a second amendment (“Second Amendment”) to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (“Pinnacle Agreement”). The Second Amendment increases the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20 million. Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes. The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12 million with the ability to increase the principal amount available for borrowing up to $20 million, upon the satisfaction of certain conditions. The Second Amendment does not affect the term of the Pinnacle Agreement, which has a three year term expiring on July 31, 2020. The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had $12.0 million in borrowings under the Pinnacle Agreement at September 30, 2018 and $9.8 million at December 31, 2018.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (resulting in an interest rate of 4.0% at September 30, 2018). In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly. Borrowings under the line of credit are collateralized by substantially all of our assets. </span></div>Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis. On August 14, 2018 the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment. The Company was in compliance with the Tangible Capital Ratio covenant as of September 30, 2018. 10000000 10000000 365648 438715 2400000 -2900000 100000000 30704 200000 233330 233525 20000000 12000000 20000000 12000000.0 9800000 0.0175 0.0275 0.040 0.0025 INCOME TAXES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (“the Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (“AMT”) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">The SEC staff issued Staff Accounting Bulletin (“SAB”) 118, providing guidance on applying the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements. If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">In connection with our analysis of the impact of the Tax Act, we have a net tax benefit of $0.1 million as of September 30, 2018. This net tax benefit consists entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. The Company does not expect to record further amounts related to the Tax Act, but will continue to evaluate additional Internal Revenue Service guidance as it is released. The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div> 100000 COLLABORATIVE AGREEMENTS<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;font-style:italic;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">. The agreements do not specifically designate each party’s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).</span> EVENT SUBSEQUENT TO THE BALANCE SHEET DATE<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">On November 6, 2018, Cumberland announced the acquisition of VIBATIV</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:6.5pt;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;"> (telavancin injection) from Theravance Biopharma U.S., Inc and Theravance Biopharma Ireland Limited (collectively, "Theravance Biopharma"). The financial terms include a $20 million payment to Theravance Biopharma upon closing, a $5 million additional payment in  early 2019 and tiered royalties up to 20% on future U.S. net product sales. The acquisition closed on November 12, 2018.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:120%;">Cumberland has a Revolving Credit Loan with Pinnacle Bank that had an initial availability of up to $12 million with the ability to increase the principal amount available for borrowing up to $20 million. On October 17, 2018, Cumberland and Pinnacle Bank increased the maximum principal available for borrowing to $20 million.  The $12 million outstanding under the Revolving Credit loan was repaid during October 2018 and the Revolving Credit Loan was then used to fund the $20 million  payment for the VIBATIV acquisition.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Times New Roman;font-size:10pt;line-height:115%;">The supplemental pro forma financial information that reflects revenue and earnings for VIBATIV is not yet being provided as the initial accounting for the business combination is not yet available to the Company as of the issuance of these financial statements. The Company will provide the supplemental pro forma financial information as it becomes available.</span></div> 20000000 5000000 0.20 12000000 20000000 20000000 12000000 20000000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Nov. 09, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name Cumberland Pharmaceuticals Inc.  
Entity Central Index Key 0001087294  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Common Stock, Shares Outstanding   15,527,623
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 38,259,233 $ 45,412,868
Marketable securities 9,533,703 4,672,476
Accounts receivable, net 7,055,138 8,395,112
Inventories, net 6,426,429 6,737,848
Other current assets 2,351,708 3,466,541
Total current assets 63,626,211 68,684,845
Property and equipment, net 539,019 528,882
Intangible assets, net 20,370,330 21,444,545
Deferred tax assets, net 87,210 87,210
Other assets 2,809,306 2,486,830
Total assets 87,432,076 93,232,312
Current liabilities:    
Accounts payable 8,447,429 8,979,929
Other current liabilities 7,070,860 8,714,814
Total current liabilities 15,518,289 17,694,743
Revolving line of credit 12,000,000.0 9,800,000
Other long-term liabilities 1,969,174 1,815,968
Total liabilities 29,487,463 29,310,711
Commitments and contingencies
Shareholders’ equity:    
Common stock—no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively 51,235,612 52,410,941
Retained earnings 6,966,252 11,709,222
Total shareholders’ equity 58,201,864 64,120,163
Noncontrolling interests (257,251) (198,562)
Total equity 57,944,613 63,921,601
Total liabilities and equity $ 87,432,076 $ 93,232,312
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 15,555,865 15,723,075
Common stock, shares outstanding (in shares) 15,555,865 15,723,075
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Net revenues $ 8,492,530 $ 11,196,961 $ 27,243,859 $ 29,500,843
Costs and expenses:        
Cost of products sold 1,460,463 2,166,353 4,511,743 5,216,776
Selling and marketing 4,803,112 6,226,438 14,549,873 16,174,391
Research and development 1,306,055 943,162 4,631,384 2,921,951
General and administrative 2,067,981 2,090,785 6,732,485 6,554,158
Amortization 661,802 609,572 1,946,457 1,811,589
Total costs and expenses 10,299,413 12,036,310 32,371,942 32,678,865
Operating income (loss) (1,806,883) (839,349) (5,128,083) (3,178,022)
Interest income 166,220 94,833 398,420 216,849
Interest expense (19,199) (8,902) (59,520) (70,646)
Income (loss) before income taxes (1,659,862) (753,418) (4,789,183) (3,031,819)
Income tax (expense) benefit (4,159) (3,822) (12,477) (4,196,192)
Net income (loss) (1,664,021) (757,240) (4,801,660) (7,228,011)
Net loss at subsidiary attributable to noncontrolling interests 20,977 14,209 58,689 49,923
Net income (loss) attributable to common shareholders $ (1,643,044) $ (743,031) $ (4,742,971) $ (7,178,088)
Earnings (loss) per share attributable to common shareholders        
- basic (in dollars per share) $ (0.11) $ (0.05) $ (0.30) $ (0.45)
- diluted (in dollars per share) $ (0.11) $ (0.05) $ (0.30) $ (0.45)
Weighted-average shares outstanding        
- basic (in shares) 15,573,108 15,867,159 15,645,230 15,973,737
- diluted (in shares) 15,573,108 15,867,159 15,645,230 15,973,737
Comprehensive income (loss) attributable to common shareholders $ (1,643,044) $ (743,031) $ (4,742,971) $ (7,178,088)
Net loss at subsidiary attributable to noncontrolling interests 20,977 14,209 58,689 49,923
Total comprehensive income (loss) $ (1,664,021) $ (757,240) $ (4,801,660) $ (7,228,011)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net income (loss) $ (4,801,660) $ (7,228,011)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization expense 2,108,051 1,974,194
Deferred tax expense 0 4,293,963
Share-based compensation 1,005,239 849,198
Excess tax (benefit) expense derived from exercise of stock options 0 (91,109)
Noncash interest expense 44,117 60,708
Noncash investment gains (131,652) (48,084)
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable 1,339,974 124,748
Inventories 311,419 (485,739)
Other current assets and other assets 966,817 (428,176)
Accounts payable and other current liabilities (1,595,243) 640,453
Other long-term liabilities 142,486 239,703
Net cash provided by (used in) operating activities (610,452) (98,152)
Cash flows from investing activities:    
Additions to property and equipment (171,731) (172,899)
Purchases of marketable securities (20,851,951) (2,029,414)
Proceeds from sale of marketable securities 16,122,376 9,644,592
Additions to intangible assets (1,411,710) (841,647)
Net cash (used in) provided by investing activities (6,313,016) 6,600,632
Cash flows from financing activities:    
Borrowings on line of credit 36,000,000 14,700,000
Repayments on line of credit (33,800,000) (10,800,000)
Proceeds from sales of common stock, net of offering costs 200,909 0
Payments of deferred offering costs (248,108) 0
Repurchase of common shares (2,382,968) (2,893,857)
Net cash provided by (used in) financing activities (230,167) 1,006,143
Net increase (decrease) in cash and cash equivalents (7,153,635) 7,508,623
Cash and cash equivalents at beginning of period 45,412,868 34,510,330
Cash and cash equivalents at end of period $ 38,259,233 $ 42,018,953
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statement of Equity - 9 months ended Sep. 30, 2018 - USD ($)
Total
Common stock
Retained earnings
Noncontrolling interests
Balance, Beginning of Period at Dec. 31, 2017 $ 63,921,601 $ 52,410,941 $ 11,709,222 $ (198,562)
Balance, Beginning of Period (in shares) at Dec. 31, 2017 15,723,075 15,723,075    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Proceeds from the sale of common stock, net of offering costs $ 200,909 $ 200,909    
Proceeds from the sale of common stock, net of offering costs (in shares)   30,704    
Share-based compensation 1,005,239 $ 1,005,239    
Share-based compensation (in shares)   167,734    
Repurchase of shares (2,381,477) $ (2,381,477)    
Repurchase of shares (in shares)   (365,648)    
Net income (loss) (4,801,660)   $ (4,742,971) (58,689)
Balance, End of Period at Sep. 30, 2018 $ 57,944,613 $ 51,235,612   $ (257,251)
Balance, End of Period (in shares) at Sep. 30, 2018 15,555,865 15,555,865    
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Basis of Presentation
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND BASIS OF PRESENTATION ORGANIZATION AND BASIS OF PRESENTATION
Cumberland Pharmaceuticals Inc. (“Cumberland,” the “Company,” or as used in the context of “we,” “us,” or “our”) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets are hospital acute care, gastroenterology, and oncology supportive care. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.
Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company’s products are manufactured by third parties, which are overseen by Cumberland’s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2017 audited consolidated financial statements, with the exception of the impacts of adopting accounting pronouncements during 2018, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the “SEC”), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2017 (the “2017 Annual Report on Form 10-K”). The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.
Total comprehensive income (loss) consisted solely of net income (loss) for the three and nine months ended September 30, 2018 and 2017.
Adoption of Revenue Recognition Accounting Standard
Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board’s (“FASB”) amended guidance in the form of Accounting Standards Update (“ASU”) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.
Net Product Revenue
Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company’s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments.
Sales Rebates and Discounts
The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.
Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company’s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a
wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company’s estimate of the rebate that may be claimed.
Sales Returns
Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company’s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.
Recent Accounting Guidance
Recent Adopted Accounting Pronouncements
In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard.
The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018. As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue.
In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows: Restricted Cash.” This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the “beginning-of-period” and “end-of-period” total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.
In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.” The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.
Recent Accounting Pronouncements - Not Yet Adopted
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.
In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-02, “Leases.” The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements
and disclosures. The Company’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023. The adoption of the new lease standard will result in the Company recording ROU assets and lease liabilities for these leases.
Accounting Policies:
Use of Estimates
In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.
Operating Segments
The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Marketable Securities
 9 Months Ended
Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]  
MARKETABLE SECURITIES MARKETABLE SECURITIES
The Company invests in marketable debt securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds, U.S. government agency issued mortgage-backed securities, U.S. government agency notes and bonds, Small Business Administration (“SBA”) loan pools, and corporate bonds. At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time. As of September 30, 2018 and December 31, 2017, the marketable securities are comprised solely of trading securities. Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the condensed consolidated statements of operations and comprehensive income (loss).
The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:
Level 1 - Quoted prices for identical instruments in active markets.
Level 2 - Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.
Level 3 -  Significant inputs to the valuation model are unobservable.
The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment. The Company has no marketable securities in which the fair value is determined based on Level 3 measurements. The level of management judgment required in evaluating fair value for Level 1 investments is minimal. Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets. Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as
derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices). There were no transfers of assets between levels within the fair value hierarchy. 
The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:
September 30, 2018 December 31, 2017 
Level 1 Level 2 Total Level 1 Level 2 Total 
U.S. Treasury notes and bonds $5,005,631 $— $5,005,631 $— $— $— 
U.S. Agency issued mortgage-backed securities – variable rate — — — — 3,539,102 3,539,102 
U.S. Agency notes and bonds – fixed rate — — — — 198,293 198,293 
Corporate bonds — 2,506,006 2,506,006 — — — 
SBA loan pools – variable rate — — — — 935,081 935,081 
Short-term cash investments — 2,022,066 2,022,066 — — — 
Total fair value of marketable securities $5,005,631 $4,528,072 $9,533,703 $— $4,672,476 $4,672,476 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings (Loss) Per Share
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE EARNINGS (LOSS) PER SHARE
The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2018 and 2017:
Three months ended September 30, 
20182017
Numerator: 
Net income (loss) attributable to common shareholders $(1,643,044)$(743,031)
Denominator: 
Weighted-average shares outstanding – basic 15,573,108 15,867,159 
Dilutive effect of other securities — — 
Weighted-average shares outstanding – diluted 15,573,108 15,867,159 
Nine months ended September 30, 
20182017
Numerator: 
Net income (loss) attributable to common shareholders $(4,742,971)$(7,178,088)
Denominator: 
Weighted-average shares outstanding – basic 15,645,230 15,973,737 
Dilutive effect of other securities — — 
Weighted-average shares outstanding – diluted 15,645,230 15,973,737 

As of September 30, 2018 and 2017, restricted stock awards and options to purchase 18,325 and 14,175 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenues
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
REVENUES REVENUES
Product Revenues
The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605. However, no cumulative effect adjustment to historical retained earnings was necessary as no revenue recognition differences were identified when comparing the revenue recognition criteria under ASC 606 to previous requirements. See further discussion in Note 1. 
The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2018 and 2017:
Three months ended September 30, Nine months ended September 30, 
2018201720182017
Products: 
Acetadote $1,122,544 $1,342,457 $3,238,284 $4,331,675 
Omeclamox-Pak 278,017 190,835 509,358 1,213,635 
Kristalose 3,017,803 2,749,966 9,490,901 8,037,994 
Vaprisol (67,436)385,541 1,712,353 1,346,793 
Caldolor 1,318,109 896,640 3,458,881 2,762,790 
Ethyol 2,593,830 2,566,611 7,659,594 8,325,254 
Totect 45,249 2,916,425 727,211 2,916,425 
Other 184,414 148,486 447,277 566,277 
Total net revenues $8,492,530 $11,196,961 $27,243,859 $29,500,843 

Other Revenues
The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories
 9 Months Ended
Sep. 30, 2018
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
The Company works closely with third parties to manufacture and package finished goods for sale. Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer. The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.
The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value. At September 30, 2018 and December 31, 2017, the Company has recognized and maintained cumulative charges for potential obsolescence and discontinuance losses of approximately $0.1 million and $0.2 million, respectively.
In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (“API”) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total at September 30, 2018 and December 31, 2017.
As of September 30, 2018 and December 31, 2017, net inventory consisted of the following:
September 30, 2018 December 31, 2017 
Raw materials and work in process $2,510,870 $3,156,002 
Consigned inventory 423,987 249,964 
Finished goods 3,491,572 3,331,882 
Total $6,426,429 $6,737,848 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Shareholders' Equity and Debt
 9 Months Ended
Sep. 30, 2018
Equity and Debt [Abstract]  
SHAREHOLDERS' EQUITY AND DEBT SHAREHOLDERS’ EQUITY AND DEBT
Share Repurchases
The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2016, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. During the nine months ended September 30, 2018 and September 30, 2017, the Company repurchased 365,648 shares and 438,715 shares, respectively, of common stock for approximately $2.4 million and $2.9 million, respectively.
Share Sale
In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. During the nine months ended September 30, 2018, the Company issued 30,704 shares of common stock for gross proceeds of $0.2 million as part of its At-The-Market (“ATM”) sales agreement with B. Riley FBR.
Restricted Share Grants
During the nine months ended September 30, 2018, and September 30, 2017, the Company issued 233,330 shares and 233,525 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the one-year anniversary of the date of grant. Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).
Debt Agreement
On October 17, 2018, the Company entered into a second amendment (“Second Amendment”) to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (“Pinnacle Agreement”). The Second Amendment increases the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20 million. Cumberland increased the maximum aggregate principal available for borrowing to support potential future acquisitions and general corporate purposes. The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12 million with the ability to increase the principal amount available for borrowing up to $20 million, upon the satisfaction of certain conditions. The Second Amendment does not affect the term of the Pinnacle Agreement, which has a three year term expiring on July 31, 2020. The Pinnacle Agreement replaced the June 2014 Revolving Credit Loan Agreement with SunTrust Bank, which was to expire on June 30, 2018. The Company had $12.0 million in borrowings under the Pinnacle Agreement at September 30, 2018 and $9.8 million at December 31, 2018.

The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (resulting in an interest rate of 4.0% at September 30, 2018). In addition, a fee of 0.25% per year is charged on the unused line of credit. Interest and the unused line fee are payable quarterly. Borrowings under the line of credit are collateralized by substantially all of our assets.
Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis. On August 14, 2018 the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment. The Company was in compliance with the Tangible Capital Ratio covenant as of September 30, 2018.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
 9 Months Ended
Sep. 30, 2018
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (“the Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (“AMT”) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.
The SEC staff issued Staff Accounting Bulletin (“SAB”) 118, providing guidance on applying the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements. If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.
In connection with our analysis of the impact of the Tax Act, we have a net tax benefit of $0.1 million as of September 30, 2018. This net tax benefit consists entirely of the release of the valuation allowance against AMT credits that will be realizable under the Tax Act in future periods. The Company does not expect to record further amounts related to the Tax Act, but will continue to evaluate additional Internal Revenue Service guidance as it is released. The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Agreements
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
COLLABORATIVE AGREEMENTS COLLABORATIVE AGREEMENTSCumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, Collaborative Agreements. The agreements do not specifically designate each party’s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Event Subsequent to the Balance Sheet Date
 9 Months Ended
Sep. 30, 2018
Subsequent Events [Abstract]  
EVENT SUBSEQUENT TO THE BALANCE SHEET DATE EVENT SUBSEQUENT TO THE BALANCE SHEET DATE
On November 6, 2018, Cumberland announced the acquisition of VIBATIV® (telavancin injection) from Theravance Biopharma U.S., Inc and Theravance Biopharma Ireland Limited (collectively, "Theravance Biopharma"). The financial terms include a $20 million payment to Theravance Biopharma upon closing, a $5 million additional payment in  early 2019 and tiered royalties up to 20% on future U.S. net product sales. The acquisition closed on November 12, 2018.

Cumberland has a Revolving Credit Loan with Pinnacle Bank that had an initial availability of up to $12 million with the ability to increase the principal amount available for borrowing up to $20 million. On October 17, 2018, Cumberland and Pinnacle Bank increased the maximum principal available for borrowing to $20 million.  The $12 million outstanding under the Revolving Credit loan was repaid during October 2018 and the Revolving Credit Loan was then used to fund the $20 million  payment for the VIBATIV acquisition.

The supplemental pro forma financial information that reflects revenue and earnings for VIBATIV is not yet being provided as the initial accounting for the business combination is not yet available to the Company as of the issuance of these financial statements. The Company will provide the supplemental pro forma financial information as it becomes available.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Recent Accounting Guidance
Recent Accounting Guidance
Recent Adopted Accounting Pronouncements
In May 2014, the FASB issued amended guidance in the form of ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of the new guidance is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The new guidance defines a five-step process to achieve this core principle and, in doing so, additional judgments and estimates may be required within the revenue recognition process. The new standard replaced most of the existing revenue recognition standards in U.S. GAAP when it became effective. In July 2015, the FASB issued a one-year deferral of the adoption date, which extended the effective date for us to January 1, 2018, at which point Cumberland adopted the standard.
The Company evaluated its revenues and the new guidance had immaterial impacts to recognition practices upon adoption on January 1, 2018. As part of the adoption, the Company elected to apply the new guidance on a modified retrospective basis. The Company did not record a cumulative effect adjustment to historical retained earnings for initially applying the new guidance as no revenue recognition differences were identified in the timing or amount of revenue.
In November 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows: Restricted Cash.” This revised standard is an effort by the FASB to reduce existing diversity in practice by providing specific guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flows. The updated guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. As such, amounts generally described as restricted cash and restricted cash equivalents should be included in the “beginning-of-period” and “end-of-period” total amounts shown on the statement of cash flows. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.
In August 2016, the FASB issued amended guidance in the form of a FASB ASU No. 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments.” The core principle of the new guidance is to address eight specific cash flow issues with the objective of reducing the existing diversity in practice. The Company adopted the new accounting pronouncement on January 1, 2018, and the adoption did not have a material impact to its statement of cash flows.
Recent Accounting Pronouncements - Not Yet Adopted
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses,” which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose significantly more information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. This standard is effective for the Company on January 1, 2020 with early adoption permitted. The Company is in the initial stage of evaluating the impact of this new standard on its trade and other receivables.
In February 2016, the FASB issued guidance in the form of a FASB ASU No. 2016-02, “Leases.” The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than twelve months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain optional practical expedients available. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating its current lease agreements for the impact of its pending adoption of the new standard on its consolidated financial statements
and disclosures. The Company’s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters. This lease currently expires in October 2022. The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by Cumberland Emerging Technologies (“CET”), our majority-owned subsidiary, where it operates the CET Life Sciences Center. This lease currently expires in April 2023. The adoption of the new lease standard will result in the Company recording ROU assets and lease liabilities for these leases.
Use of Estimates
Use of Estimates
In preparing the condensed consolidated financial statements in conformity with U.S. GAAP, management must make decisions that impact the reported amounts and the related disclosures. Such decisions include the selection of the appropriate accounting principles to be applied and the assumptions on which to base accounting estimates. In reaching such decisions, management applies judgments based on its understanding and analysis of the relevant circumstances, historical experience, and other available information. Actual results could differ from those estimates under different assumptions and conditions. The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns and (2) the allowances for obsolescent or unmarketable inventory.
Operating Segments Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances. Substantially all of the Company’s assets are located in the United States and total revenues are primarily attributable to U.S. customers.
Revenue Recognition
Adoption of Revenue Recognition Accounting Standard
Effective January 1, 2018, the Company adopted the Financial Accounting Standards Board’s (“FASB”) amended guidance in the form of Accounting Standards Update (“ASU”) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and are reported in accordance with ASC 605.
Net Product Revenue
Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 45 days from date of shipment. The Company’s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments.
Sales Rebates and Discounts
The allowances against accounts receivable for chargebacks, discounts, expired and damaged goods are determined on a product-by-product basis, and established by management as the Company’s best estimate at the time of sale based on each product’s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and credits claimed for damaged and expired product.
Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company’s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a
wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company’s estimate of the rebate that may be claimed.
Sales Returns
Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company’s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Marketable Securities (Tables)
 9 Months Ended
Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]  
Fair value of marketable securities, by type
The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:
September 30, 2018 December 31, 2017 
Level 1 Level 2 Total Level 1 Level 2 Total 
U.S. Treasury notes and bonds $5,005,631 $— $5,005,631 $— $— $— 
U.S. Agency issued mortgage-backed securities – variable rate — — — — 3,539,102 3,539,102 
U.S. Agency notes and bonds – fixed rate — — — — 198,293 198,293 
Corporate bonds — 2,506,006 2,506,006 — — — 
SBA loan pools – variable rate — — — — 935,081 935,081 
Short-term cash investments — 2,022,066 2,022,066 — — — 
Total fair value of marketable securities $5,005,631 $4,528,072 $9,533,703 $— $4,672,476 $4,672,476 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings (Loss) Per Share (Tables)
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Reconciliation of numerator and denominator
The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three and nine months ended September 30, 2018 and 2017:
Three months ended September 30, 
20182017
Numerator: 
Net income (loss) attributable to common shareholders $(1,643,044)$(743,031)
Denominator: 
Weighted-average shares outstanding – basic 15,573,108 15,867,159 
Dilutive effect of other securities — — 
Weighted-average shares outstanding – diluted 15,573,108 15,867,159 
Nine months ended September 30, 
20182017
Numerator: 
Net income (loss) attributable to common shareholders $(4,742,971)$(7,178,088)
Denominator: 
Weighted-average shares outstanding – basic 15,645,230 15,973,737 
Dilutive effect of other securities — — 
Weighted-average shares outstanding – diluted 15,645,230 15,973,737 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenues (Tables)
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Summary of net revenue
The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2018 and 2017:
Three months ended September 30, Nine months ended September 30, 
2018201720182017
Products: 
Acetadote $1,122,544 $1,342,457 $3,238,284 $4,331,675 
Omeclamox-Pak 278,017 190,835 509,358 1,213,635 
Kristalose 3,017,803 2,749,966 9,490,901 8,037,994 
Vaprisol (67,436)385,541 1,712,353 1,346,793 
Caldolor 1,318,109 896,640 3,458,881 2,762,790 
Ethyol 2,593,830 2,566,611 7,659,594 8,325,254 
Totect 45,249 2,916,425 727,211 2,916,425 
Other 184,414 148,486 447,277 566,277 
Total net revenues $8,492,530 $11,196,961 $27,243,859 $29,500,843 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Tables)
 9 Months Ended
Sep. 30, 2018
Inventory Disclosure [Abstract]  
Inventory
As of September 30, 2018 and December 31, 2017, net inventory consisted of the following:
September 30, 2018 December 31, 2017 
Raw materials and work in process $2,510,870 $3,156,002 
Consigned inventory 423,987 249,964 
Finished goods 3,491,572 3,331,882 
Total $6,426,429 $6,737,848 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Basis of Presentation Organization (Details)
 9 Months Ended
Sep. 30, 2018
Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments 1
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Marketable Securities (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Debt Securities, Available-for-sale [Line Items]    
Marketable securities $ 9,533,703 $ 4,672,476
U.S. Treasury notes and bonds    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 5,005,631 0
U.S. Agency issued mortgage-backed securities – variable rate    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 3,539,102
U.S. Agency notes and bonds – fixed rate    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 198,293
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 2,506,006 0
SBA loan pools – variable rate    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 935,081
Short-term cash investments    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 2,022,066 0
Level 1    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 5,005,631 0
Level 1 | U.S. Treasury notes and bonds    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 5,005,631 0
Level 1 | U.S. Agency issued mortgage-backed securities – variable rate    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 0
Level 1 | U.S. Agency notes and bonds – fixed rate    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 0
Level 1 | Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 0
Level 1 | SBA loan pools – variable rate    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 0
Level 1 | Short-term cash investments    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 0
Level 2    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 4,528,072 4,672,476
Level 2 | U.S. Treasury notes and bonds    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 0
Level 2 | U.S. Agency issued mortgage-backed securities – variable rate    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 3,539,102
Level 2 | U.S. Agency notes and bonds – fixed rate    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 198,293
Level 2 | Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 2,506,006 0
Level 2 | SBA loan pools – variable rate    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities 0 935,081
Level 2 | Short-term cash investments    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities $ 2,022,066 $ 0
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings (Loss) Per Share (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Numerator:        
Net income (loss) attributable to common shareholders $ (1,643,044) $ (743,031) $ (4,742,971) $ (7,178,088)
Denominator:        
Weighted-average shares outstanding – basic (in shares) 15,573,108 15,867,159 15,645,230 15,973,737
Dilutive effect of other securities (in shares) 0 0 0 0
Weighted-average shares outstanding – diluted (in shares) 15,573,108 15,867,159 15,645,230 15,973,737
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Earnings (Loss) Per Share (Details Textual) - shares
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Earnings Per Share [Abstract]    
Common stock available for purchase through restricted stock awards and options (in shares) 18,325 14,175
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenues (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Products:        
Net revenues $ 8,492,530 $ 11,196,961 $ 27,243,859 $ 29,500,843
Acetadote        
Products:        
Net revenues 1,122,544 1,342,457 3,238,284 4,331,675
Omeclamox-Pak        
Products:        
Net revenues 278,017 190,835 509,358 1,213,635
Kristalose        
Products:        
Net revenues 3,017,803 2,749,966 9,490,901 8,037,994
Vaprisol        
Products:        
Net revenues (67,436) 385,541 1,712,353 1,346,793
Caldolor        
Products:        
Net revenues 1,318,109 896,640 3,458,881 2,762,790
Ethyol        
Products:        
Net revenues 2,593,830 2,566,611 7,659,594 8,325,254
Totect        
Products:        
Net revenues 45,249 2,916,425 727,211 2,916,425
Other        
Products:        
Net revenues $ 184,414 $ 148,486 $ 447,277 $ 566,277
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Details) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Inventory    
Raw materials and work in process $ 2,510,870 $ 3,156,002
Consigned inventory 423,987 249,964
Finished goods 3,491,572 3,331,882
Total $ 6,426,429 $ 6,737,848
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Details Textual) - USD ($)
$ in Millions
Sep. 30, 2018
Dec. 31, 2017
Inventory Disclosure [Abstract]    
Reserve for potential obsolescence of products $ 0.1 $ 0.2
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)
 1 Months Ended 9 Months Ended
Nov. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Jan. 31, 2016
May 13, 2010
Shareholders' Equity (Textual) [Abstract]          
Repurchase outstanding common shares       $ 10,000,000 $ 10,000,000
Repurchase of shares, value   $ (2,381,477)      
Shelf Registration, sale of corporate securities (up to) $ 100,000,000        
Proceeds from sales of common stock, net of offering costs   $ 200,909 $ 0    
Restricted Stock          
Shareholders' Equity (Textual) [Abstract]          
Restricted stock granted in period, shares   233,330 233,525    
Director | Restricted Stock          
Shareholders' Equity (Textual) [Abstract]          
Restricted stock awards, vesting period   1 year      
Common stock          
Shareholders' Equity (Textual) [Abstract]          
Repurchase of shares (in shares)   365,648 438,715    
Repurchase of shares, value   $ (2,381,477) $ 2,900,000    
Proceeds from the sale of common stock, net of offering costs (in shares)   30,704      
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Shareholders' Equity and Debt (Debt) (Details) - USD ($)
Jul. 31, 2017
Oct. 17, 2018
Sep. 30, 2018
Dec. 31, 2017
Line of Credit Facility [Line Items]        
Revolving line of credit     $ 12,000,000.0 $ 9,800,000
Pinnacle Bank | Second Amendment | Revolving Credit Facility | Subsequent Event        
Line of Credit Facility [Line Items]        
Line of credit, maximum borrowing capacity   $ 20,000,000    
Pinnacle Bank | Line of Credit | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Line of credit, maximum borrowing capacity upon satisfaction of certain conditions $ 20,000,000   20,000,000  
Expiration period 3 years      
Line of credit, maximum borrowing capacity $ 12,000,000   $ 12,000,000  
Line of credit, unused capacity, commitment fee percentage 0.25%      
Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum        
Line of Credit Facility [Line Items]        
Interest rate spread 1.75%      
Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum        
Line of Credit Facility [Line Items]        
Interest rate spread 2.75%      
SunTrust Bank | Line of Credit | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Effective interest rate     4.00%  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Details Textual) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Income Tax Disclosure [Abstract]    
Deferred tax assets, net $ 87,210 $ 87,210
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Event Subsequent to the Balance Sheet Date (Details) - USD ($)
 1 Months Ended
Nov. 06, 2018
Oct. 31, 2018
Oct. 17, 2018
Sep. 30, 2018
Jul. 31, 2017
Pinnacle Bank | Line of Credit | Revolving Credit Facility          
Subsequent Event [Line Items]          
Line of credit, maximum borrowing capacity upon satisfaction of certain conditions       $ 20,000,000 $ 20,000,000
Line of credit, maximum borrowing capacity       $ 12,000,000 $ 12,000,000
Subsequent Event | Pinnacle Bank | Line of Credit | Revolving Credit Facility          
Subsequent Event [Line Items]          
Repayments on revolving credit loan   $ 12,000,000      
Subsequent Event | Pinnacle Bank | Second Amendment | Revolving Credit Facility          
Subsequent Event [Line Items]          
Line of credit, maximum borrowing capacity     $ 20,000,000    
Subsequent Event | VIBATIV          
Subsequent Event [Line Items]          
Payment to acquire business upon closing $ 20,000,000        
Additional payment to acquire business $ 5,000,000        
Percentage of tiered royalty payments (up to) 20.00%        
EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 105 131 1 false 30 0 false 5 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.cumberlandpharma.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statement of Equity Sheet http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity Condensed Consolidated Statement of Equity Statements 6 false false R7.htm 2101101 - Disclosure - Organization and Basis of Presentation Sheet http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation Organization and Basis of Presentation Notes 7 false false R8.htm 2104102 - Disclosure - Marketable Securities Sheet http://www.cumberlandpharma.com/role/MarketableSecurities Marketable Securities Notes 8 false false R9.htm 2107103 - Disclosure - Earnings (Loss) Per Share Sheet http://www.cumberlandpharma.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 9 false false R10.htm 2111104 - Disclosure - Revenues Sheet http://www.cumberlandpharma.com/role/Revenues Revenues Notes 10 false false R11.htm 2114105 - Disclosure - Inventories Sheet http://www.cumberlandpharma.com/role/Inventories Inventories Notes 11 false false R12.htm 2118106 - Disclosure - Shareholders' Equity and Debt Sheet http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt Shareholders' Equity and Debt Notes 12 false false R13.htm 2121107 - Disclosure - Income Taxes Sheet http://www.cumberlandpharma.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 2123108 - Disclosure - Collaborative Agreements Sheet http://www.cumberlandpharma.com/role/CollaborativeAgreements Collaborative Agreements Notes 14 false false R15.htm 2124109 - Disclosure - Event Subsequent to the Balance Sheet Date Sheet http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDate Event Subsequent to the Balance Sheet Date Notes 15 false false R16.htm 2202201 - Disclosure - Organization and Basis of Presentation (Policies) Sheet http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies Organization and Basis of Presentation (Policies) Policies 16 false false R17.htm 2305301 - Disclosure - Marketable Securities (Tables) Sheet http://www.cumberlandpharma.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.cumberlandpharma.com/role/MarketableSecurities 17 false false R18.htm 2308302 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.cumberlandpharma.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://www.cumberlandpharma.com/role/EarningsLossPerShare 18 false false R19.htm 2312303 - Disclosure - Revenues (Tables) Sheet http://www.cumberlandpharma.com/role/RevenuesTables Revenues (Tables) Tables http://www.cumberlandpharma.com/role/Revenues 19 false false R20.htm 2315304 - Disclosure - Inventories (Tables) Sheet http://www.cumberlandpharma.com/role/InventoriesTables Inventories (Tables) Tables http://www.cumberlandpharma.com/role/Inventories 20 false false R21.htm 2403401 - Disclosure - Organization and Basis of Presentation Organization (Details) Sheet http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails Organization and Basis of Presentation Organization (Details) Details 21 false false R22.htm 2406402 - Disclosure - Marketable Securities (Details) Sheet http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails Marketable Securities (Details) Details http://www.cumberlandpharma.com/role/MarketableSecuritiesTables 22 false false R23.htm 2409403 - Disclosure - Earnings (Loss) Per Share (Details) Sheet http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails Earnings (Loss) Per Share (Details) Details http://www.cumberlandpharma.com/role/EarningsLossPerShareTables 23 false false R24.htm 2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual) Sheet http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual Earnings (Loss) Per Share (Details Textual) Details http://www.cumberlandpharma.com/role/EarningsLossPerShareTables 24 false false R25.htm 2413405 - Disclosure - Revenues (Details) Sheet http://www.cumberlandpharma.com/role/RevenuesDetails Revenues (Details) Details http://www.cumberlandpharma.com/role/RevenuesTables 25 false false R26.htm 2416406 - Disclosure - Inventories (Details) Sheet http://www.cumberlandpharma.com/role/InventoriesDetails Inventories (Details) Details http://www.cumberlandpharma.com/role/InventoriesTables 26 false false R27.htm 2417407 - Disclosure - Inventories (Details Textual) Sheet http://www.cumberlandpharma.com/role/InventoriesDetailsTextual Inventories (Details Textual) Details http://www.cumberlandpharma.com/role/InventoriesTables 27 false false R28.htm 2419408 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details) Sheet http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails Shareholders' Equity and Debt (Shareholders' Equity) (Details) Details http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt 28 false false R29.htm 2420409 - Disclosure - Shareholders' Equity and Debt (Debt) (Details) Sheet http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails Shareholders' Equity and Debt (Debt) (Details) Details http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt 29 false false R30.htm 2422410 - Disclosure - Income Taxes (Details Textual) Sheet http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) Details http://www.cumberlandpharma.com/role/IncomeTaxes 30 false false R31.htm 2425411 - Disclosure - Event Subsequent to the Balance Sheet Date (Details) Sheet http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails Event Subsequent to the Balance Sheet Date (Details) Details http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDate 31 false false All Reports Book All Reports cpix-20180930.htm cpix-20180930.xsd cpix-20180930_cal.xml cpix-20180930_def.xml cpix-20180930_lab.xml cpix-20180930_pre.xml cpixq32018-exhibit101.htm cpixq32018-exhibit311.htm cpixq32018-exhibit312.htm cpixq32018-exhibit321.htm http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cpix-20180930.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 105, "dts": { "calculationLink": { "local": [ "cpix-20180930_cal.xml" ] }, "definitionLink": { "local": [ "cpix-20180930_def.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml" ] }, "inline": { "local": [ "cpix-20180930.htm" ] }, "labelLink": { "local": [ "cpix-20180930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-doc-2018-01-31.xml" ] }, "presentationLink": { "local": [ "cpix-20180930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2018/dei-ref-2018-01-31.xml" ] }, "schema": { "local": [ "cpix-20180930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" ] } }, "elementCount": 230, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 10, "http://xbrl.sec.gov/dei/2018-01-31": 9, "total": 19 }, "keyCustom": 6, "keyStandard": 125, "memberCustom": 14, "memberStandard": 16, "nsprefix": "cpix", "nsuri": "http://www.cumberlandpharma.com/20180930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.cumberlandpharma.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - Revenues", "role": "http://www.cumberlandpharma.com/role/Revenues", "shortName": "Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114105 - Disclosure - Inventories", "role": "http://www.cumberlandpharma.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118106 - Disclosure - Shareholders' Equity and Debt", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt", "shortName": "Shareholders' Equity and Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121107 - Disclosure - Income Taxes", "role": "http://www.cumberlandpharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123108 - Disclosure - Collaborative Agreements", "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements", "shortName": "Collaborative Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124109 - Disclosure - Event Subsequent to the Balance Sheet Date", "role": "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDate", "shortName": "Event Subsequent to the Balance Sheet Date", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)", "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies", "shortName": "Organization and Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Marketable Securities (Tables)", "role": "http://www.cumberlandpharma.com/role/MarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - Earnings (Loss) Per Share (Tables)", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables", "shortName": "Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - Revenues (Tables)", "role": "http://www.cumberlandpharma.com/role/RevenuesTables", "shortName": "Revenues (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "0", "lang": null, "name": "us-gaap:MarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315304 - Disclosure - Inventories (Tables)", "role": "http://www.cumberlandpharma.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)", "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails", "shortName": "Organization and Basis of Presentation Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Marketable Securities (Details)", "role": "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails", "shortName": "Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i9b9ec509678b4c49909a3ea728188b2e_D20180701-20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Earnings (Loss) Per Share (Details)", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails", "shortName": "Earnings (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i9b9ec509678b4c49909a3ea728188b2e_D20180701-20180930", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual", "shortName": "Earnings (Loss) Per Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i9b9ec509678b4c49909a3ea728188b2e_D20180701-20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Revenues (Details)", "role": "http://www.cumberlandpharma.com/role/RevenuesDetails", "shortName": "Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "contextRef": "i637cb0f284da4777ae7513edeab98505_D20180701-20180930", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Inventories (Details)", "role": "http://www.cumberlandpharma.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - Inventories (Details Textual)", "role": "http://www.cumberlandpharma.com/role/InventoriesDetailsTextual", "shortName": "Inventories (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i336e8e712e374b2f8e79006273c92b86_I20160131", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419408 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails", "shortName": "Shareholders' Equity and Debt (Shareholders' Equity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i336e8e712e374b2f8e79006273c92b86_I20160131", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermLineOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420409 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)", "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails", "shortName": "Shareholders' Equity and Debt (Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i77bf42c5f31341c6892029d58d366991_D20170731-20170731", "decimals": "INF", "lang": null, "name": "us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ia4c7fcfb77744a29a511c1d25b651a12_I20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - Income Taxes (Details Textual)", "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual", "shortName": "Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i13d0929f4b074f5d8f441c1de94e9011_I20180930", "decimals": "INF", "first": true, "lang": null, "name": "cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425411 - Disclosure - Event Subsequent to the Balance Sheet Date (Details)", "role": "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "shortName": "Event Subsequent to the Balance Sheet Date (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "i7236191012f64ee88a32bcfcd1e8a5b1_D20181001-20181031", "decimals": "6", "lang": null, "name": "us-gaap:RepaymentsOfLinesOfCredit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i9b9ec509678b4c49909a3ea728188b2e_D20180701-20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i9b9ec509678b4c49909a3ea728188b2e_D20180701-20180930", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "ied88402e0e774670b7c92a62ace059d9_I20171231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity", "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "shortName": "Condensed Consolidated Statement of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "contextRef": "iad418ae038084c7c837d59fa9e26cb88_I20171231", "decimals": "0", "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Basis of Presentation", "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation", "shortName": "Organization and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Marketable Securities", "role": "http://www.cumberlandpharma.com/role/MarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - Earnings (Loss) Per Share", "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "i929cd12c7a8f41b481ce3e8aca0698b7_D20180101-20180930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 30, "tag": { "cpix_AcetadoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acetadote", "label": "Acetadote [Member]", "terseLabel": "Acetadote" } } }, "localname": "AcetadoteMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_AdditionalPaymentsToAcquireBusinesses": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Additional Payments to Acquire Businesses", "label": "Additional Payments to Acquire Businesses", "terseLabel": "Additional payment to acquire business" } } }, "localname": "AdditionalPaymentsToAcquireBusinesses", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails" ], "xbrltype": "monetaryItemType" }, "cpix_CaldolorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Caldolor", "label": "Caldolor [Member]", "terseLabel": "Caldolor" } } }, "localname": "CaldolorMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_DenominatorAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Denominator.", "label": "Denominator [Abstract]", "verboseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "cpix_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and entity information.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.cumberlandpharma.com/20180930", "xbrltype": "stringItemType" }, "cpix_EquityAndDebtAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity and Debt [Abstract]", "label": "Equity and Debt [Abstract]" } } }, "localname": "EquityAndDebtAbstract", "nsuri": "http://www.cumberlandpharma.com/20180930", "xbrltype": "stringItemType" }, "cpix_EthyolMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ethyol", "label": "Ethyol [Member]", "terseLabel": "Ethyol" } } }, "localname": "EthyolMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "label": "IncreaseDecreaseInCurrentOperatingLiabilities", "verboseLabel": "Accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInCurrentOperatingLiabilities", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "cpix_KristaloseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Kristalose", "label": "Kristalose [Member]", "terseLabel": "Kristalose" } } }, "localname": "KristaloseMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions", "label": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions", "terseLabel": "Line of credit, maximum borrowing capacity upon satisfaction of certain conditions" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "cpix_LoanPoolsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "LoanPoolsMember", "terseLabel": "SBA loan pools \u2013 variable rate" } } }, "localname": "LoanPoolsMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "cpix_NumeratorAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Numerator.", "label": "Numerator [Abstract]", "verboseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "cpix_OmeclamoxPakMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Omeclamox-Pak", "label": "Omeclamox-Pak [Member]", "terseLabel": "Omeclamox-Pak" } } }, "localname": "OmeclamoxPakMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_OtherLongTermObligationsExcludingCurrentPortion": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Long Term Obligations, Excluding Current Portion", "label": "Other Long Term Obligations, Excluding Current Portion", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLongTermObligationsExcludingCurrentPortion", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "cpix_OtherProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Products", "label": "Other Products [Member]", "terseLabel": "Other" } } }, "localname": "OtherProductsMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_PinnacleBankMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pinnacle Bank", "label": "Pinnacle Bank [Member]", "terseLabel": "Pinnacle Bank" } } }, "localname": "PinnacleBankMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "cpix_ProductsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Products.", "label": "Products [Abstract]", "verboseLabel": "Products:" } } }, "localname": "ProductsAbstract", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "cpix_SecondAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second Amendment", "label": "Second Amendment [Member]", "terseLabel": "Second Amendment" } } }, "localname": "SecondAmendmentMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "cpix_ShareholdersEquityTextualAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shareholders Equity.", "label": "Shareholders Equity (Textual) [Abstract]", "verboseLabel": "Shareholders' Equity (Textual) [Abstract]" } } }, "localname": "ShareholdersEquityTextualAbstract", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities", "terseLabel": "Shelf Registration, sale of corporate securities (up to)" } } }, "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cpix_SunTrustBankMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SunTrustBankMember", "terseLabel": "SunTrust Bank" } } }, "localname": "SunTrustBankMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "cpix_TieredRoyaltyPaymentsPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tiered Royalty Payments, Percentage", "label": "Tiered Royalty Payments, Percentage", "terseLabel": "Percentage of tiered royalty payments (up to)" } } }, "localname": "TieredRoyaltyPaymentsPercentage", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails" ], "xbrltype": "percentItemType" }, "cpix_TotectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Totect", "label": "Totect [Member]", "terseLabel": "Totect" } } }, "localname": "TotectMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "cpix_UsTreasuryNotesAndBondsSecuritiesMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Us Treasury Notes And Bonds Securities Member", "label": "Us Treasury Notes And Bonds Securities Member [Member]", "terseLabel": "U.S. Treasury notes and bonds" } } }, "localname": "UsTreasuryNotesAndBondsSecuritiesMemberMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "cpix_VIBATIVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VIBATIV", "label": "VIBATIV [Member]", "terseLabel": "VIBATIV" } } }, "localname": "VIBATIVMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails" ], "xbrltype": "domainItemType" }, "cpix_VaprisolMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vaprisol", "label": "Vaprisol [Member]", "terseLabel": "Vaprisol" } } }, "localname": "VaprisolMember", "nsuri": "http://www.cumberlandpharma.com/20180930", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r98", "r127", "r129", "r203" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r15", "r128" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AgencySecuritiesMember": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Securities issued by government sponsored entities.", "label": "Agency Securities [Member]", "terseLabel": "U.S. Agency notes and bonds \u2013 fixed rate" } } }, "localname": "AgencySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r48", "r63", "r172" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "verboseLabel": "Noncash interest expense" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r63", "r114", "r116" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r81" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r96", "r181", "r195" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r39" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r136", "r141" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r151", "r152" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r25", "r65" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "COLLABORATIVE AGREEMENTS" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CollaborativeAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r118", "r186", "r200" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r122" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance, End of Period (in shares)", "periodStartLabel": "Balance, Beginning of Period (in shares)", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r41", "r43", "r44" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r41", "r43", "r158", "r159", "r165" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Net loss at subsidiary attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r41", "r43", "r157", "r165" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income (loss) attributable to common shareholders" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r50" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "verboseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r49" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r11", "r12", "r182", "r183", "r194" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r32", "r121", "r171" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate spread" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r63", "r68", "r147", "r148" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred tax expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": { "auth_ref": [ "r144", "r145", "r146" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Assets, Net, Noncurrent", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r63", "r94" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DirectorMember": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).", "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "verboseLabel": "Earnings (loss) per share attributable to common shareholders" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r47", "r74", "r77", "r78", "r79", "r80", "r83", "r189", "r202" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "- basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r47", "r74", "r77", "r78", "r79", "r80", "r83", "r189", "r202" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "- diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS (LOSS) PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": { "auth_ref": [ "r142" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.", "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities", "negatedLabel": "Excess tax (benefit) expense derived from exercise of stock options" } } }, "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r167", "r168", "r169" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Fair value of marketable securities, by type" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r131", "r132", "r133", "r169", "r176" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r131", "r132", "r133", "r169", "r177" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r131", "r132", "r133", "r169", "r178" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r115" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "verboseLabel": "Intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r71" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r68", "r95", "r149" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (expense) benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r62" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r62" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Net changes in assets and liabilities affecting operating activities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r62" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other current assets and other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r45", "r93", "r170", "r172", "r190" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r20", "r112" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "verboseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r37", "r110" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total", "verboseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]", "verboseLabel": "Inventory" } } }, "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r21", "r112" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "verboseLabel": "Raw materials and work in process" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r37", "r73", "r110", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "verboseLabel": "Reserve for potential obsolescence of products" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesDetailsTextual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r52", "r92" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r109", "r180", "r193", "r204" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "MARKETABLE SECURITIES" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r185", "r198" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r28", "r69" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityExpirationPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Line of Credit Facility, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "LineOfCreditFacilityExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r28", "r69" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of credit, unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r33", "r119", "r120" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit, Noncurrent", "verboseLabel": "Revolving line of credit" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r187" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r36", "r184", "r197" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember": { "auth_ref": [ "r102", "r131" ], "lang": { "en-US": { "role": { "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by non-governmental sponsored enterprises.", "label": "Mortgage-backed Securities, Issued by Private Enterprises [Member]", "terseLabel": "U.S. Agency issued mortgage-backed securities \u2013 variable rate" } } }, "localname": "MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Short-term cash investments" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r61", "r64" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r40", "r42", "r46", "r64", "r82", "r188", "r201" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss) attributable to common shareholders", "totalLabel": "Net income (loss) attributable to common shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r40", "r42", "r161", "r164" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss at subsidiary attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Guidance" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "verboseLabel": "Noncontrolling interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r166" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "verboseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": { "auth_ref": [ "r37" ], "calculation": { "http://www.cumberlandpharma.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.", "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross", "terseLabel": "Consigned inventory" } } }, "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r5", "r6", "r30" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r56" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common shares" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r58" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Payments of deferred offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r53", "r153" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payment to acquire business upon closing" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r54" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Additions to intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r101" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r54" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r55" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from sales of common stock, net of offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r72" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Borrowings on line of credit" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sale of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r40", "r42", "r59", "r96", "r97", "r157", "r160", "r162", "r164", "r165" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r9", "r117", "r199" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r57", "r70" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "terseLabel": "Repayments on revolving credit loan" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r57" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Repayments on line of credit" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r143", "r205" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r81" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r123", "r196" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r125", "r126", "r127" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenues", "verboseLabel": "Net revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r67", "r130" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Net Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r103", "r104", "r105", "r106", "r107", "r108", "r191", "r192" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of numerator and denominator" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r98" ], "lang": { "en-US": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r98" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Summary of net revenue" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/RevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r7", "r22", "r23", "r24" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r136", "r141" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "REVENUES" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/Revenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "verboseLabel": "Operating Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "verboseLabel": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r62" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Restricted stock awards, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r139" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock granted in period, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r134", "r138" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r35", "r122" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r122", "r123" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Proceeds from the sale of common stock, net of offering costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r13", "r14", "r122", "r123" ], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Share-based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r122", "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Proceeds from the sale of common stock, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r13", "r14", "r123", "r135", "r140" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Share-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "verboseLabel": "Repurchase outstanding common shares" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r13", "r14", "r122", "r123" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of shares (in shares)", "terseLabel": "Repurchase of shares (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r13", "r14", "r122", "r123" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Repurchase of shares", "negatedTerseLabel": "Repurchase of shares, value" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r100" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r155", "r156", "r163" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance, End of Period", "periodStartLabel": "Balance, Beginning of Period", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "verboseLabel": "Equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDateDetails", "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "EVENT SUBSEQUENT TO THE BALANCE SHEET DATE" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EventSubsequenttotheBalanceSheetDate" ], "xbrltype": "textBlockItemType" }, "us-gaap_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Relationship to Entity [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Marketable securities" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/MarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r63" ], "calculation": { "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Noncash investment gains" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r85", "r86", "r87", "r88", "r89", "r90", "r91" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r80" ], "calculation": { "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Dilutive effect of other securities (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r76", "r80" ], "calculation": { "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)", "verboseLabel": "- diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r75", "r80" ], "calculation": { "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)", "verboseLabel": "- basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss", "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=SL6283291-111563" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11374-113907" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r206": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" } }, "version": "2.0" } ZIP 50 0001628280-18-014380-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-18-014380-xbrl.zip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η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end